1	Title: Repurposing of Glatiramer Acetate to Treat Heart Diseases
2	One Sentence Summary: Glatiramer acetate promotes reparative processes in rodent models of
3	cardiac injury and reduces the inflammatory process in ADHF patients.
4	Authors: Gal Aviel ¹ , Jacob Elkahal ¹ , Kfir Baruch Umansky ¹ , Hanna Bueno-Levy ¹ , Shoval
5	Miyara ¹ , Daria Lendengolts ¹ , Lingling Zhang ¹ , Zachary Petrover ¹ , David Kain ¹ , Tali Shalit ² ,
6	Rina Aharoni ³ , Ruth Arnon ³ , David Mishaly ⁴ , Uriel Katz ^{4,5} , Dean Nachman ⁶ , Mahdi Ammar ⁶ ,
7	Rabea Asleh ⁶ , Offer Amir ⁶ , Eldad Tzahor ^{1*} , Rachel Sarig ^{1*}
8	
9	Affiliations:
10	¹ The Department of Molecular Cell Biology, Weizmann Institute of Science; Rehovot, Israel.
11	² Bioinformatics unit, G-INCPM, Weizmann Institute of Science; Rehovot, Israel.
12	³ The Department of Immunology and Regenerative Biology, Weizmann Institute of Science,
13	Rehovot, Israel.
14	⁴ Pediatric Heart Institute, Edmond and Lily Safra Children's Hospital, Sheba Medical Center,
15	Tel Hashomer, Israel.
16	⁵ Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
17	⁶ Heart Institute, Hadassah Medical Center and Faculty of Medicine, Hebrew University,
18	Jerusalem, Israel.
19	
20	* Corresponding authors' email: <u>rachel.sarig@weizmann.ac.il</u> (R.S.);
21	eldad.tzahor@weizmann.ac.il (E.T.)

23 Abstract:

Myocardial injury may ultimately lead to adverse ventricular remodeling and development 24 of heart failure (HF), which is a major cause of morbidity and mortality worldwide. Given the slow 25 pace and substantial costs of developing new therapeutics, drug repurposing is an attractive 26 alternative. Studies of many organs, including the heart, highlight the importance of the immune 27 28 system in modulating injury and repair outcomes. Glatiramer-acetate (GA) is an immunomodulatory drug prescribed for patients with multiple sclerosis. Here we report that short-29 term GA treatment improves cardiac function and reduces scar area in a mouse model of acute 30 31 myocardial infarction, as well as in a rat model of ischemic HF. We provide both in vivo and in vitro mechanistic evidence indicating that in addition to its immunomodulatory functions, GA 32 exerts beneficial pleiotropic effects, including cardiomyocyte protection and enhanced 33 angiogenesis, mediated partially by extracellular vesicles carrying a pro-reparative cargo. Finally, 34 as GA is a widely used drug with established efficacy and safety history, we conducted a small, 35 prospective, randomized trial to determine its effect on patients admitted to the hospital with acute 36 decompensated HF (ADHF). Strikingly, a short-term add-on administration of GA, resulted in 37 marked reduction in the cytokine surge and NT-proBNP levels, both associated with acute HF 38 39 exacerbations. Overall, these findings demonstrate the efficacy of GA in attenuating acute myocardial injury and modulating the inflammatory process in animal models and humans and 40 41 highlight the potential of GA as a future therapy for a myriad of heart diseases.

- 42
- 43
- 44
- 45
- 46

47 Main Text:

48 **INTRODUCTION**

49 Heart failure (HF) is a leading cause of morbidity and mortality worldwide. While improvements in revascularization techniques and medical care have significantly reduced 50 mortality rates from acute myocardial infarction (MI), the incidence of ischemic cardiomyopathy 51 is increasing ¹. The pathogenesis of HF is intricately related to a chronic inflammatory process, 52 leading to irreversible loss of cardiomyocytes (CMs)². While a transient inflammation is essential 53 for tissue healing, including cardiac repair ^{3,4}, a maladaptive immune response may contribute to 54 adverse left ventricle (LV) remodeling and development of chronic HF. The idea of using 55 immunomodulatory drugs to ameliorate LV remodeling and improve heart function after acute MI 56 57 has been tested in several clinical trials which yielded conflicting results⁵.

The development of new drugs is a laborious, long-term, and costly process ⁶. Hence, 58 repurposing approved drugs to treat new indications is an appealing strategy for expanding the 59 60 therapeutic armamentarium to treat patients. Glatiramer acetate (GA) is a synthetic random 61 copolymer composed of four amino acids that has been used for years for the treatment of multiple 62 sclerosis (MS)⁷. Originally, GA was designed to resemble the autoantigen myelin basic protein and shown to have beneficial effects in animal model of MS, experimental autoimmune 63 encephalomyelitis⁸, yet multiple studies revealed its broad immunomodulatory and anti-64 inflammatory mechanism of action, at different levels of both the innate and the adaptive immune 65 66 responses ^{9,10}. As such, GA binds promiscuously to major histocompatibility complex (MHC) molecules, acting both as an MHC blocker ¹¹ and a T cell receptor antagonist ¹², leading to 67 inhibition of pathological effector functions. GA has also been shown to modulate the properties 68 of dendritic cells and monocytes to preferentially stimulate type 2 helper T (Th2) cell-like 69

responses ¹³, inducing the secretion of anti-inflammatory cytokines ^{14,15} and elevation of T-70 regulatory cells (Tregs)¹⁶. GA-induced Th2 cells and Tregs were shown to accumulate in the 71 injury site and secrete *in situ* anti-inflammatory cytokines and growth factors that suppress the 72 inflammation and augment repair processes ^{17,18}. Based on its broad immunomodulatory mode of 73 action, potential applications of GA for additional pathologies were investigated, showing its 74 beneficial effects in prevention of immune rejection ¹⁹, improvement of stem cells engraftment ²⁰, 75 amelioration of inflammatory bowel disease (IBD) ^{21,22}, and repair of liver fibrosis ²³. Due to the 76 immunomodulatory mechanism of action of GA, its efficacy in various pathological systems, and 77 78 its broad safety profile, we hypothesized that it might mitigate the pathological inflammatory process associated with myocardial injury, thereby preventing its progression, and improving 79 cardiac outcomes. 80

In the present work, we initiated a drug repurposing process of GA for the treatment of 81 heart diseases from the preliminary pre-clinical work in murine models of acute myocardial 82 ischemia to the completion of a phase 2a clinical trial in patients with HF. First, we tested the 83 potential application of GA for improving heart function using murine models of myocardial 84 ischemia. Our data show beneficial pleiotropic effects of GA treatment on the injured heart, 85 86 manifested by improved cardiac function and reduced scar area in a mouse model of acute MI as well as in a rat model of HF. Examination of GA's mode-of-action revealed that in addition to its 87 88 known immunomodulatory effects, shown here for the first time in the context of myocardial 89 inflammation, it promoted CM protection from ischemia-induced death, reduced fibrosis and enhanced angiogenesis. Administration of extracellular vesicles (EVs) isolated from GA-treated 90 91 hearts recapitulated GA's effects in a mouse model of acute MI, suggesting that these beneficial

paracrine effects were mediated by EVs. *In vitro* and *ex vivo* assays further supported a paracrine
effect of stromal cells on CMs.

Next, we proceeded to conduct a small phase 2a, open-label, randomized-controlled 94 clinical trial to assess the potential and safety of GA treatment in patients hospitalized with ADHF. 95 GA therapy added to standard HF therapy resulted in a significant blunting of the cytokine surge 96 97 associated with ADHF and improvement in HF severity, as represented by a remarkable reduction in the levels of the natriuretic peptide NT-proBNP, compared to standard HF therapy alone. 98 Overall, our data reveal novel protective and reparative effects of GA in rodent models of cardiac 99 100 ischemia, as well as its safety and beneficial effects in ADHF patients. Collectively, these results highlight the potential of repurposing GA as a future therapy for patients with heart diseases. 101

102

103 **RESULTS**

104 Transient treatment with GA results in improved cardiac function after acute MI

105 Searching for drug candidates that could be repurposed to treat heart diseases, we postulated that the beneficial immunomodulatory effects of GA could be harnessed to promote 106 myocardial repair. To test this hypothesis, we subjected adult mice to acute MI²⁴ and divided into 107 108 two groups, receiving daily intraperitoneal (i.p) injections of either GA or solvent as a control for 109 14 days, starting from the day of surgery (Fig. 1A). While transthoracic echocardiography 110 confirmed the presence of a significant injury in both groups 2 days post-injury (dpi), at 35 dpi, a 111 significant improvement in systolic function was apparent only in the GA-treated group, as displayed by both ejection fraction (EF) and fractional shortening (FS) (Fig. 1B,C). Quantification 112 113 of the scar area in histological sections showed a significant reduction in infarct size following GA treatment (Fig. 1D,E). In addition, stratification of scar area according to size revealed that large 114

scars, encompassing more than 30% of LV volume, were present only in the control group. GA treatment yielded similar results also when calculating ischemic area-at-risk and infarct zone at 4 dpi (Fig. 1F,G), excluding the possibility of surgical inconsistencies in the findings and ensuring the quality control of the procedure.

Subsequently, we tested whether the therapeutic window for GA administration might be extended, which is relevant for the treatment of late-arrival MI patients²⁵. To that end, mice were subjected to MI and treatment was postponed for 24- or 48-hours post-MI. Results showed that delayed administration of GA improved systolic function to a similar extent as compared to immediate treatment (Fig. 1H). This suggests a wide temporal window for GA administration, relevant for late arrival patients.

125

GA treatment attenuates acute inflammatory response and promotes a pro-reparative immune phenotype after acute MI

128 Following acute MI, the ischemic myocardium activates an intense inflammatory response, mostly of the innate immune system, followed by infiltration of neutrophils and bone marrow-129 derived monocytes. The early dominance of innate immunity is then replaced by an adaptive 130 immune response ²⁶. Based on the known immunomodulatory effects of GA in various models of 131 organ injury ^{23,27,28}, we postulated that it would inhibit the acute inflammatory response following 132 133 MI and promote a pro-reparative immune phenotype. To gain deeper insights on the effects of GA 134 on the inflammatory response following acute MI, we performed single-cell expression profiling on CD45+-enriched cardiac cells at 1 and 4 dpi, using the 10x Genomics Chromium platform. 135 136 Adult mice were subjected to acute MI and treated daily with either GA or control until their 137 sacrifice (Fig. 2A). Echocardiography performed at 3 dpi demonstrated a significant beneficial

effect in the GA-treated group on %EF already at this early timepoint, indicating a potential protective effect of GA on the ischemic myocardium (Fig. 2B). Transcriptional profiles of 49,369 cells were captured after quality control filtering. Distinct cell populations, represented by a total of 19 clusters, were visualized in uniform manifold approximation and projection (UMAP) reduced dimensionality plots (Fig. 2C and Fig. S1A). Cluster annotation was performed using canonical markers for each cell type (Fig. 2C and Methods).

Neutrophils are the first immune cells to infiltrate the myocardium in response to injury, 144 peak at day 1 and quickly undergo apoptosis thereafter ²⁹. As expected, neutrophils were the 145 predominant immune cells detected at 1 dpi (~26.3% of total cells), and by day 4 their numbers 146 substantially decreased to 5.6% of total cells (Fig. 2D), validating the injury. The 147 monocytic/macrophage population demonstrated opposite kinetics, comprising 26% of total cells 148 in 1 dpi, and increasing to 48.5% by day 4. Of note, at 1 dpi the majority of Cd68+ monocytes 149 were Lyve1+Timd4+ resident cardiac macrophages, which were further increased at 4 dpi due to 150 the accumulation of Lyve1-Timd4+ macrophages (Fig. 2D). Another validation for the injury can 151 be shown by the activation of *Colla1+Postn+* myofibroblasts that increased by 12-fold at 4 dpi 152 (Fig. 2D). 153

The average abundance of T- and B-cells was largely constant (~4% each, not shown), consistent with the known slower kinetic of adaptive immunity ³⁰. Excessive neutrophil activation has been associated with increased infarct sizes due to the increased tissue damage ³¹ and with occurrence of fatal ventricular fibrillation ³². We identified a distinct neutrophil cluster based on canonical markers (Fig. 2E). Differential gene analysis comparing the GA and Control groups at 1 dpi demonstrated 726 differentially expressed genes (DEG) as well as down-regulation in neutrophil activation markers such as *S100a8* and *S100a9* in the GA group (Fig. 2F-G). These

genes bind to Toll-like receptors and activate inflammasome-dependent pathways, thereby 161 intensifying inflammatory activation, resulting in increased damage ³³. Ingenuity pathway analysis 162 (IPA) of DEG demonstrated in the GA treated mice down regulation in pathways related to 163 Inflammatory response, and upregulation in pathways related to Free radical scavenging, 164 Senescence, STAT3 and Autophagy, associated with neutrophil silencing and clearance from the 165 tissue ³⁴ (Fig. 2H). To substantiate these findings, we analyzed neutrophil myocardial infiltration 166 at 1 dpi using FACS, which demonstrated that GA administration had resulted in a significant 167 reduction in their numbers (Fig. 2I and Fig. S1B). The attenuation of the inflammatory response 168 at 1 dpi was further demonstrated by the significant reduction observed in serum levels of pro-169 inflammatory cytokines induced by GA treatment (Fig. 2J). 170

Th2 cells and Tregs play an essential role in the resolution phase of tissue injury and in 171 promoting repair processes in various tissues, including the heart ³⁵. The immunomodulation 172 activity of GA in patients with MS includes the stimulation of Th2-like responses ¹³, with 173 concomitant elevation of Tregs ^{16,36}. We detected a distinct cluster of Cd3e+Cd3d+T cells (Fig. 174 2K). IPA performed on the DEG between GA and control at 4 dpi revealed down-regulation in 175 numerous pathways related to immune activation and upregulation in a pathway related to Treg 176 177 cells (Fig. 2L). Immunostaining and flow cytometry demonstrated elevation in Tregs levels in GA-treated hearts (Fig. 2M and Fig. S1C), indicating that in addition to the immediate effect of 178 179 GA on the pro-inflammatory response, it can also modulate the immune response in the injured 180 heart towards reparative inflammation.

In the regenerative murine neonatal heart, tissue-resident macrophages expand and dominate the injured area, resulting in reduced inflammation, enhanced angiogenesis, and CM proliferation ⁸. However, in adult mice, this resident macrophage population is replaced, or

outnumbered, by monocyte-derived macrophages that are prominently pro-inflammatory⁸. Thus, 184 coordinated temporal activation of distinct macrophage populations might be essential for cardiac 185 healing. We detected a cluster of *Timd4*+ resident cardiac macrophages that expanded in size by 186 4 dpi (Fig. 2K lower panel). IPA performed on the DEG between GA and control at 4 dpi revealed 187 metabolic signatures favoring *Glycolysis*, *Gluconeogenesis* and *cellular growth and proliferation*. 188 In addition, we noted a down regulation in pathways related to *Il-6 Signaling* and *natural killer* 189 cell signaling, which could reflect a reparative phenotype induced by the Timd4+ resident 190 macrophages (Fig. 2L). To corroborate this, we followed the dynamics of cardiac macrophage 191 192 profiles at 4 dpi using FACS and detected a significant increase in the levels of TIMD4+ resident cardiac macrophages that limit adverse remodeling after MI ³⁷ in the hearts of GA-treated mice 193 (Fig. 2M). 194

Taken together, our data support an early anti-inflammatory effect induced by GA treatment. This is demonstrated by transcriptomic changes indicating reduced neutrophil activation, reduced myocardial infiltration of neutrophils, as well as by reduction in serum proinflammatory cytokines. Additionally, we provide evidence that GA induces a pro-reparative immune phenotype, reflected by transcriptomic changes seen at single cell level of T cells and cardiac resident macrophages, which are further supported by FACS and immunofluorescence analyses.

202

Single cell profiling suggests multiple effects on endothelial and fibroblasts induced by GA treatment following MI

The single cell suspensions for the scRNA-seq experiment were enriched for CD45+ to mainly focus on the myocardial immune response following GA treatment. As expected, the

9

samples also contained 11708 non-immune cells (mainly endothelial cells (EC) and cardiac 207 fibroblasts (CF)). To gain better insight on these populations, we re-clustered them and generated 208 an unbiased targeted UMAP for each population (Fig. S2A and Fig. 3A-C). The ECs consisted of 209 6 different clusters: lymphatic, venous, arterial, and 3 distinct capillary endothelial clusters (Fig. 210 S2A). IPA performed on the DEG at 1 dpi of the general endothelial cluster demonstrated 211 212 enrichment in pathways related to Vasculogenesis, cell survival and cell movement and down regulation in pathways related to cell death of endothelial cells in the GA group compared to 213 control. This reflects a possible protective and proangiogenic effect induced as early as 1 day 214 following GA treatment (Fig. S2B). Capillary sub-clustering consisted of Capillary-1 and 215 Capillary-2 were detected at 1 dpi whereas Capillary-3 emerged only at 4 dpi (Fig. S2C). A 216 Frequency plot revealed that the GA-treated group was enriched for Capillary-1, while Capillary-217 2 was more prevalent in the control group (Fig. S2D). Further pathway analysis demonstrated that 218 Capillary-1 cluster is enriched with pathways related to *blood vessel morphogenesis* and various 219 220 angiogenesis pathways, whereas the Capillary-2 cluster was enriched with inflammatory pathways, including pathways related to interleukin-1 beta production and leukocyte cell-cell 221 adhesion, further supporting an angiogenic effect of GA (Fig. 2SE-F). 222

The CF UMAP consisted of a distinct cluster of myofibroblasts and quiescent fibroblasts, 2clusters of pericytes, and a distinct monocytic cluster (Fig. S3A). The monocytic cluster that was found in the targeted UMAP of both fibroblasts and endothelial cells expressed both monocytic gene markers as well as endothelial- or fibroblasts- markers, probably reflecting stromal cell phagocytosis by recruited monocytes/macrophages (Figs. S2A and S3B). As expected, these monocytes were absent at 1 dpi and appeared only at 4 dpi, reflecting the known kinetics of monocytic recruitment to the tissue. Pathway analysis of DEG revealed an intense activation of

fibroblasts at 1 dpi in the GA- treated group compared to control, with enrichment of pathways 230 related to Wound Healing Signaling (Fig. S3D, left). The analysis at 4 dpi demonstrated an 231 opposite expression pattern, characterized by profound silencing of fibroblast activation, as 232 evidenced by down regulation in pathways related to Wound Healing, and various pathways of 233 Fibrosis (Fig. S3D, right). These data suggest that GA might induce a biphasic fibroblast activation 234 235 response, characterized by an early acute activation, required for the immediate response, followed by a profound inactivation, that could reduce the deposition of collagen and the progression of 236 fibrosis. 237

Overall, these data suggest that GA affects the transcriptome of cardiac ECs and fibroblasts. In fibroblasts it induces a biphasic activation and silencing pattern, and in ECs it promotes the protection and angiogenic responses.

241

Extracellular vesicles isolated from GA-treated hearts carry a pro-reparative cargo and can recapitulate the beneficial effects of GA after acute MI

Next, we explored the impact of GA therapy on the proteomic landscape at 4 dpi. Here too, 244 echocardiography of injured mice performed at 3 dpi indicated that the decline in systolic 245 246 parameters was mitigated in GA-treated mice, indicating a potential protective effect of GA on the ischemic myocardium (Fig. 3A,B). Principle component analysis (PCA) performed at 4 dpi 247 248 revealed three distinct clusters according to the treatment (uninjured, MI-control, MI-GA) (Fig. 249 3C). A total of 93 DE proteins were detected in the control group and 178 in the GA group (Fig. 3D). Pathway analysis of the DE proteins showed enrichment in pathways of innate immunity, 250 251 leukocyte chemotaxis, T cell proliferation, and cell motility and migration in the GA treated hearts, 252 all consistent with substantial modulation of the immune response (Fig. 3E). In addition, we noted

a significant enrichment in proteins related to extracellular vesicles (EVs) (Fig. 3E). EVs are
membrane-containing organelles, of 30-120 nm in diameter, which are secreted through
exocytosis, carrying distinct cargo capable of exerting a myriad of effects, including repair ^{38,39}.
Additionally, the protective effect of endothelial cell-derived EVs was recently shown in a human
heart-on-chip model ⁴⁰, suggesting that GA could act by paracrine signaling mediated by EVs.

258 We therefore examined whether cardiac EVs derived from GA-treated animals can recapitulate the beneficial effects of GA on cardiac function after injury. For that, we isolated 259 cardiac EVs from mice subjected to acute MI (Fig. S4A-D). Based on the proteomic analysis 260 results, animals were treated for 3 days with either GA or control and on day 4 EVs were isolated 261 from the LV and were administered immediately after LAD ligation to a second cohort of mice 262 (Fig. 3F). Consistent with the proteomic data, a significant reduction in %EF values was apparent 263 in animals that received a single intramyocardial injection of control-derived EVs or PBS (Fig. 264 3G,H). Notably, the reduction in systolic function was blunted by administration of EVs derived 265 266 from GA-treated mice (Fig. 3G,H). In addition to functional cardiac improvement, histological analysis revealed a significant reduction in infarct size following GA-derived EV treatment, 267 compared to control-treated hearts (Fig. 3I,J). As myocardial perfusion is a major determinant of 268 269 cardiomyocyte death following acute ischemia, we assessed arterial density in the infarct zone. A 270 significant increase in α SMA+ blood vessels and in CD31+ cells was observed in mice that were 271 treated with GA-derived EVs compared to control EVs at 4dpi (Fig 3I-K, Fig S5), suggesting that GA-derived EVs exert a protective effect on myocardial coronary arteries. The strong α SMA+ 272 staining observed inside the scar region, mainly in control hearts, reflects activated myofibroblasts. 273 Taken together, our results suggest a protective effect of GA-derived EVs on CMs and coronary 274 275 vasculature.

To analyze the differential protein content of cardiac EVs derived from GA- or control-276 treated hearts, we performed proteomic analysis of these vesicles. PCA revealed three distinct 277 clusters: GA-derived, control-derived EVs, or EVs from uninjured hearts (Fig. 3L), indicating GA-278 dependent differences. Overall, 455 proteins were found to be significantly changed in the GA-279 derived EVs (Fig. 3M). GA-derived EVs exhibited significant enrichment in numerous gene 280 281 ontology (GO) terms, such as negative regulation of apoptotic processes, cardiac contractility, respiratory chain, mitochondrion, and ribosome (Fig. 3N). A targeted heatmap based on the 282 individual proteins that comprise these pathways further highlighted distinct proteins in GA-283 derived EVs that might be involved in improving systolic function or exerting CM protective 284 effects, such as Birc6, SERCA2 and phospholamban (Fig. 3O). Together, these results reveal a 285 distinct myocardial proteomic signature induced by GA therapy, which is associated with pro-286 reparative EV secretion that can recapitulate GA's reparative effects. 287

288

GA promotes cardiac tissue protection, angiogenesis, and reduced cardiac fibroblast proliferation

An immediate detrimental effect of tissue ischemia is loss of CMs due to necrotic and 291 apoptotic cell death. Apoptotic cell death starts already 2h after injury and can last for weeks ⁴¹. 292 Based on the proteomic data demonstrating enrichment in anti-apoptotic pathways (Fig. 3N,O), 293 294 and the consistent preserved systolic functions already at 3 dpi (Fig. 2B and Fig. 3A,B), we 295 hypothesized that reduced levels of apoptosis would be detected after GA treatment. Indeed, TUNEL assay at 24h and 96h post-injury revealed less apoptotic CMs in the ischemic border zone 296 297 of GA-treated hearts (Fig. 4A-E). Additionally, we observed an increase in the expression of the 298 anti-apoptotic protein, Bcl-XL, in the border zone and injured area of GA-treated mice (Fig.

S6A,B), indicating an immediate protective effect of GA on the injured heart. These findings were further supported using a 3D *ex vivo* organ culture (EVOC) model of adult mouse hearts (Fig. S6D-H), where we exposed cardiac slices to H_2O_2 , a reactive oxygen species (ROS) that causes cellular damage, thereby mimicking the pathophysiology of reperfusion injury. TUNEL assay and IF of γ H2AX revealed reduced levels of DNA double-strand breaks in GA treated samples (Fig. S6D-H), suggesting a protective effect of GA also in the *ex vivo* model.

While early cardiac fibroblast (CF) activation is vital for replacing the scaffold of necrotic tissue, late and excessive CF proliferation can impair proper heart function due to stiffening of the myocardium ⁴². Staining heart sections with vimentin and Ki67 revealed intensive migration of CFs to the injured site in both GA-treated and control hearts 24h after injury (Fig. 4F). Yet, at 96h post-MI, GA suppressed CF proliferation within the scar region, relative to control (Fig. 4F,G).

310 Following the observed protective effects of GA and the induction of reparative inflammation, we next addressed its capacity to induce repair processes. A crucial aspect of the 311 repair process after MI is the restoration of blood supply to the ischemic myocardium. Adequate 312 angiogenesis can improve myocardial perfusion as well as crosstalk between CMs and endothelial 313 cells (ECs), which improves CM function through angiocrine signals ⁴³. Quantification of CD31⁺ 314 cells revealed enhanced capillary formation within the scar area of GA-treated hearts (Fig. 4H,I), 315 316 which was accompanied by ~5-fold increase of blood vessels (Fig. 4E,F), at 14 dpi (Fig. 4J,K). This suggests that in addition to the protective effect of GA, which results in enhanced survival of 317 blood vessels at the injured site, it can induce endothelial cell proliferation. 318

Taken together, these results demonstrate that GA treatment exerts pleiotropic beneficial effects that include CM protection, modulation of fibroblast activation, induction of a reparative

inflammatory response and enriched vascularization, leading to improved cardiac repair and
 function following MI (Fig. S7).

323

GA confers protection of cultured cardiomyocytes from stress-induced cell death in a cell non-autonomous manner

326 While the neuroprotective effects of GA are mainly attributed to its immunomodulatory properties, in vitro data suggest that it has a direct protective effect on cultured neurons in the 327 absence of immune cells ⁴⁴. To determine whether GA exerts a protective effect on CMs 328 independent of immune cells, we used an in vitro cardiac culture model. Flow cytometry verified 329 that the cultures contained negligible amounts of immune cells (Fig. S8A). Cardiac cultures 330 derived from 3 days old (P3) mice were treated with the pro-apoptotic agent staurosporine (STS) 331 or with H₂O₂. Cell death and apoptosis were analyzed using DAPI exclusion or TUNEL assays, 332 respectively, with or without GA. CMs that were treated with STS for 18 hours in the presence of 333 334 GA displayed reduced apoptosis and cell death (Fig. 5A and Fig. S8B). Control CMs under STSinduced stress lost their typical morphology and intact sarcomeric structure, whereas most GA-335 treated CMs maintained a typical appearance (Fig. 5A). Additionally, 48h after the addition of 336 337 STS, more CMs survived in GA-treated cultures compared to control (Fig. 5B). Similarly, exposure of cardiac cultures to H₂O₂ revealed a significant protection of CMs in GA-treated 338 339 cultures compared to control (Fig. 5C).

Cultured cardiac cells derived from P3 mice contain various cell types, including CMs, CFs and ECs. To detect the localization of GA in these cells, we administered GA conjugated to FITC (FITC-GA) and then labeled specific cell types using immunofluorescence staining. FITC-GA maintained its activity and induced a similar protective effect *in vitro* as unlabeled GA (Fig.

S8C). Accumulation of FITC-GA started rapidly after its administration (Fig. 5D). As previously 344 described, GA was localized in the cytoplasm of labeled cells ⁴⁴, most of them positive for CD31 345 or vimentin (Fig. 5D). Interestingly, while CMs were not labeled even after prolonged incubation 346 of 48h, they localized around the FITC-GA-labeled cell clusters. Labeling was also quite negligible 347 in myofibroblasts, as shown by lack of FITC-GA in cells expressing SMA (Fig. 5D). The EVOC 348 349 model of adult hearts showed a similar pattern of FITC-GA labeled cells, which accumulated mainly in interstitial cells and not in CMs (Fig. 5E), further supporting a paracrine effect exerted 350 351 by neighboring stromal cells on the CMs.

The in vivo data indicating involvement of GA-derived EVs in mediating GA's therapeutic 352 effect, together with the absence of FITC-GA from CMs, strongly suggest a cell non-autonomous 353 signaling as the mechanism of action whereby GA induces CM protection. To test this hypothesis, 354 we used conditioned media from CM-depleted cardiac cultures (Fig. S8D), that were treated with 355 either GA or control. After washing the residual GA, conditioned media was collected and used 356 357 for ROS assay, i.e., challenge with H₂O₂ (Fig. S8E). GA-conditioned media from CM-depleted cultures reduced CM mortality following ROS exposure compared to control conditioned media 358 (Fig. S8F), further verifying that GA acts in a paracrine manner via fibroblasts and ECs. 359

360

GA induces spatial organization of cardiomyocytes and endothelial cells, while inhibits mouse and human CF proliferation

Next, we examined the effect of GA treatment on the growth of distinct cardiac cell populations *in vitro*. While we detected no effect on CM proliferation (not shown), GA treatment promoted the accumulation of ECs (Fig. 5F,G), further corroborating the findings obtained from the scRNA-seq analysis and the enhanced vascularization observed *in vivo*. To determine the long-

term effects of GA on cardiac cultures, we followed the fate of CMs and ECs for up to 14 days of 367 culture in the presence of GA. Immunostaining revealed a striking difference in the spatial 368 organization of CMs. While in the absence of GA, CMs were randomly dispersed as usually 369 observed in cardiac cultures (Fig. 5H, left panels), in GA-treated cultures, CMs rearranged in a 370 process resembling tube formation. Co-staining revealed that GA induced tight association of 371 372 CD31+ ECs with CMs (Fig. 5H, right panels). This spatial organization of ECs and CMs was previously shown to promote improved survival and beating of CMs ⁴⁵, as well as cardiac 373 remodeling and regeneration ⁴³. RT-qPCR analysis verified the enrichment of both CM and EC 374 populations in prolonged GA-treated cultures (Fig. 5I). Thus, GA triggers spatial association 375 between CMs and ECs, leading to their enhanced survival. In accordance with the *in vivo* data, GA 376 inhibited the proliferation of cultured CFs derived from either mouse hearts (Fig. S8G,H) or human 377 cardiac biopsies (Fig. S8I). 378

Taken together, our *in vitro* data correlate with the observed effects of GA *in vivo* and *ex vivo*, showing that in addition to its pro-reparative immunomodulatory activity, GA directly promotes beneficial effects *in vitro* by improving CM survival, enhancing angiogenesis, and reducing CF proliferation.

383

384 Transient treatment with GA improves heart function in a rat model of heart failure

Despite dramatic improvements in interventional cardiology that, over the past three decades, have reduced the mortality associated with acute MI, the prevalence of HF is on the rise. HF is associated with chronic inflammation. Our results in the acute MI mouse model prompted us to determine whether treatment with GA could have beneficial effects on the failing heart. For that, we induced MI in a rat model of permanent LAD ligation, allowing post-MI ventricular

remodeling to progress for 28 days before starting treatment with GA or a control solvent. The 390 severity of the injury was determined by monitoring EF values three weeks post-MI, after which 391 the rats were divided into two experimental groups with similar measurements (Fig. 6A). The 392 development of HF was validated by detection of ventricular remodeling by echocardiography 393 (based on LV internal diameter in diastole) and upregulation of *nppb* in cardiac tissue (Fig. 6B,C). 394 395 To prime GA-induced immunomodulation, rats were first treated with i.p GA injections daily for 7 days, followed by three weekly injections for 2 months. Echocardiography measurements were 396 performed at the end of treatment (93 days) and 1 month later (120 days). After 2 months of 397 398 treatment, the GA group displayed a significant improvement in cardiac function, as shown by a mean increase of $\sim 30\%$ in EF and $\sim 59\%$ in FS parameters, compared to the control group (Fig. 399 6D-F). Remarkably, 1 month after discontinuation of GA therapy, further improvement was 400 observed in EF (48% increase), and the improvement in FS values was maintained (45% increase), 401 in the GA treated group (Fig. 6E,F, and https://youtu.be/xKbnnBUaKF4, https://youtu.be/Zlu-402 gET60e4). Examination of individual rats revealed that most of GA-treated animals had improved 403 EF and FS values, whereas control rats displayed worsened parameters (Fig. 6G,H). In addition to 404 improvement in systolic function, GA-treated rats demonstrated reduced adverse remodeling of 405 406 the LV, reflected by the reduced LV dimensions (Fig. 6I,J). While the control group demonstrated a persistent increase in interstitial fibrosis from 21 to 120 dpi, GA significantly inhibited this 407 408 increased collagen deposition as shown by Masson Trichrome staining (Fig. 6K). These results 409 suggest that a short 2-month GA treatment regimen results in persistent beneficial remodeling effects on the LV, reduced myocardial fibrosis and enhanced LV contractility. 410

411

412 GA treatment blunts the cytokine surge associated with ADHF and reduces serum levels of

413 NT-proBNP in a small phase 2a clinical study

The clinical syndrome of HF involves a vicious cycle where myocardial and systemic 414 inflammatory processes cause further ventricular and hemodynamic deterioration ⁴⁶. Based on the 415 effects we observed on myocardial injury in rodents and its excellent safety profile in humans, we 416 417 postulated that GA could be repurposed to treat myocardial injury by preventing cardiac remodeling. To test this, we conducted a small proof-of-concept, phase 2a, open-label, 418 419 randomized-controlled trial to assess the effects of GA treatment on the inflammatory profile of patients admitted to the hospital due to ADHF. Briefly, patients were eligible for participating if 420 they had a confirmed diagnosis of HF with reduced systolic function (EF $\leq 40\%$), were clinically 421 stable for the preceding month and on maximally tolerated guideline-directed medical therapy 422 (GDMT) for at least 3 months. Major exclusion criteria included acute coronary syndrome, current 423 infection, active treatment with anti-inflammatory agents or low compliance to medical therapy. 424 425 Patients were randomly assigned in a 1:1 ratio, to receive GDMT alone or GDMT in addition to daily subcutaneous injections of GA (20mg daily), for 14 days. Baseline echocardiography was 426 available for all patients at the time of enrollment. Patients were followed closely during 427 428 hospitalization and up to 3 months thereafter. Blood samples were collected at days 0, 2, and 14 (Fig. 7A). The primary outcome was a change in serum inflammatory profile from baseline to days 429 430 2 and 14. Secondary outcomes included serum levels of cardiac biomarkers (high-sensitivity 431 troponin and NT-proBNP), creatine kinase, and repeated hospitalizations due to ADHF within 3 months of follow-up. As this was the first clinical trial testing GA effects on patients with HF, we 432 evaluated safety parameters, including adverse reactions, kidney function (using serum creatinine 433 434 levels) and liver function (by monitoring liver enzymes).

Between June 2021 and June 2022, 67 patients admitted to the participating medical center 435 with ADHF were screened. Of them, 14 patients who met the inclusion criteria were recruited. 436 Eight patients were randomized to the GA plus GDMT group, and 6 to the GDMT alone group 437 (Fig. 7B). Two patients (one from each group) that required in-patient cardiac catheterization were 438 excluded from the analysis of primary outcome. There were no significant differences in baseline 439 440 characteristics between the two groups (Fig. S9A and Fig. 7C). GA therapy resulted in a significant blunting of the cytokine surge associated with ADHF starting early at day 2 and maintained at day 441 14 following hospital admission (Fig. 7D). While the levels of serum cytokines in the standard 442 care group increased from baseline measurements to day 14, GA-treated patients had significantly 443 lower cytokine levels both at days 2 and 14. A post hoc analysis of individual cytokines performed 444 after exclusion of 2 patients with abnormally high cytokine levels at day 14 (1 from each group), 445 demonstrated a consistent trend of GA-mediated reduction throughout the various types of 446 cytokines analyzed (Fig. 7E). 447

NT-proBNP is a natriuretic peptide that is mainly secreted by ventricular CMs in response 448 to wall stretch associated with volume overload and elevated filling pressures, which are the sine 449 qua non of ADHF. This cardiac biomarker serves for diagnostic as well prognostic purposes with 450 excellent correlation with HF severity and response to therapy ⁴⁷. Therefore, we examined changes 451 in NT-proBNP circulatory levels in these ADHF patients with and without GA therapy. GA 452 453 treatment resulted in a significant reduction in serum levels of NT-proBNP at days 2 (45%) and 454 14 (57%) after normalization to baseline levels (Fig. 7F, left), whereas in the control group, NTproBNP levels increased by 10% and 31%, respectively (Fig. 7F, p=0.03 for both time points). 455 When comparing the change in NT-proBNP values between baseline and day 14, a clear decrease 456 457 in NT-proBNP levels was observed in the GA-treated group (-59%), while NT-proBNP levels

were increased in the control group (+112%) (Fig. 7F, right and Fig. S9B). Scatter plot of cytokines 458 and NT-proBNP levels revealed two distinct clusters of treated versus untreated patients (Fig. 7G). 459 460 As an exploratory clinical outcome, we recorded the rate of re-hospitalizations due to HF during the first 3 months from the index hospitalization. Three patients (25%) were re-admitted to the 461 hospital due to HF exacerbation (1/7 in the GA group and 2/5 in the control group) (Fig. S9C), 462 463 thus the study was underpowered to show statistically significant differences. We did not detect significant differences in plasma levels of myocardial injury markers (high-sensitivity troponin or 464 creatine kinase, data not shown). There were no mortality events observed during the follow-up 465 period. No adverse reactions were reported throughout the course of the study, and no changes in 466 complete blood counts and kidney or liver function were noted. 467

Lastly, we performed proteomic analysis of EV-enriched sera from all patients at baseline, 468 day 2 and day 14 (Fig. S10A-C). While baseline PCA did not show separate clustering of the 469 standard care and GA groups, a separate cluster of GA-treated patients was evident at days 2 and 470 471 14 (Fig. S10D). An unsupervised heat map generated from differentially expressed (DE) proteins at day 2 revealed a clear proteomic signature of the GA-treated patients (Fig. S10E). The main DE 472 proteins were matricellular proteins (Tenascin, SPARCL1) that are associated with extracellular 473 474 matrix remodeling, as well as proteins related to tissue stress (PRDX2 and KDM4C) (Fig. S10F). These data, obtained by an unbiased, high-throughput assay, further demonstrate the broad impact 475 of GA treatment. 476

477

478 **DISCUSSION**

We show here for the first time that the immunomodulator drug GA can induce reparative processes in rodent models of acute MI and ischemic HF and to significantly suppress the cytokine surge associated with ADHF in hospitalized patients. Our study is thus unique in combining basic

preclinical research along with a small clinical trial suggesting GA as a potential new therapy for
 heart diseases. This study also stresses the potential of drug repurposing strategy, which markedly
 accelerates the process of drug development.

Acute MI triggers intense activation of the immune system that is required for the repair 485 process, promoting clearance of necrotic debris, and initiating a pro-regenerative tissue response 486 ⁴⁸. The various stages and components of immune cell activation must be strictly regulated to 487 prevent secondary myocardial damage, adverse remodeling, and the development of HF. As GA 488 is primarily known for its immune modulating effects, we initially performed a through 489 490 characterization of the cardiac inflammatory response following GA treatment, revealing multiple beneficial effects on neutrophils, macrophages, and T cells. These effects encompassed extensive 491 changes in gene expression profiles, evaluated at the single cell level, as well as in immune cell 492 tissue infiltration and cytokine secretion. It has been previously shown that an acute immune 493 response can account for the beneficial effects attributed to cardiac stem cell therapy, specifically 494 by modulating regional macrophages subtypes ⁴⁹. The combined effects of reduced neutrophil 495 activation together with up regulation in TIMD4+ resident cardiac macrophages and Tregs is 496 expected to culminate in less collateral myocardial damage and a pro-reparative *milieu*. Indeed, 497 498 we detected reduced CM apoptosis as early as 24h following injury, coinciding with the peak of neutrophil infiltration. In addition, we observed reduced CF activation, coronary vasculature 499 500 protection and increased angiogenesis. We subsequently showed the therapeutic effects of GA in 501 a rat model of ischemic HF, which further substantiated the broad capability of GA to prevent deterioration of the injured heart and enhance the reparative process. 502

503 Interestingly, apart from the known immune-modulating activity of GA, we provide 504 evidence for pleiotropic effects *in vitro* in cardiac cultures lacking immune cells, which include

22

CM protection and angiogenesis. The specific uptake of FITC-conjugated GA by CFs and ECs but 505 not CMs, as well as the protective paracrine effects of GA-treated conditioned medium collected 506 from CM-depleted cardiac cultures, suggest that these effects are, at least partly, mediated by 507 secreted factors. The in vivo results of GA-derived cardiac EVs, which are enriched with proteins 508 that promote anti-apoptotic effects and enzymes that participate in oxidative phosphorylation, 509 510 support the paracrine effects observed *in vitro*, and suggest that these vesicles could also improve CM metabolism. Taken together, we propose that GA exerts a bidirectional effect; on one hand, it 511 promotes CM protection that results in reduced immune activation, and, on the other hand, it 512 attenuates the acute immune response, thereby minimizing secondary tissue damage (Fig. S7). 513

Inflammation contributes to the pathogenesis and progression of HF, and specifically of 514 acute exacerbations ⁴⁶. The magnitude of the inflammatory response in ADHF patients was found 515 to be in correlation with the serum levels of NT-proBNP and is associated with a considerable risk 516 of death within the subsequent 12 months from hospitalization ^{50,51}. Therefore, we decided to test 517 the efficacy of GA in inhibiting the cytokine surge associated with ADHF, thus potentially 518 improving cardiovascular outcomes in this patient subset. It is important to note that the objective 519 of this clinical study was to provide preliminary human data on the safety and potential efficacy 520 521 of GA therapy to reduce the cytokine surge, neurohormonal activation and myocardial hemodynamic stress among patients with ADHF. The efficacy and high safety profile of GA have 522 been documented in many clinical trials in large cohorts of patients treated for extended time 523 periods ⁵²⁻⁵⁴. However, the drug has not been previously tested in patients with a heart disease, and 524 there is a previous theoretical assumption that GA may be responsible for modulating the risk of 525 coronary artery disease ⁵⁵. Importantly, we did not observe any adverse effects in the treated 526 527 patients, though larger patient cohorts will be necessary to confirm the safety of GA for this

indication. Consistent with the results obtained in our preclinical models, we noted a profound 528 general reduction in the levels of both pro- and anti- inflammatory cytokines after a short-term 529 treatment with GA. The general silencing of both pro- and anti- inflammatory mediators promoted 530 by GA is consistent with previous reports, demonstrating worse outcomes in patients in whom the 531 general cytokine surge was not decayed ^{50,51}. In addition, we detected significant reductions in the 532 533 levels of NT-proBNP in the GA-treated group. As hospitalized patients with ADHF whose NTproBNP levels remain high despite treatment are at substantially increased risk of death ⁵⁶, GA's 534 effects on natriuretic peptides might be a surrogate for improved clinical outcomes. 535

Taken together, our findings indicate that GA may have an advantage in promoting 536 myocardial repair over other immune-modulating agents tested thus far, as it not only targets 537 several different aspects of the immune response and drives a pro-reparative immune phenotype, 538 but also exerts multiple pleiotropic effects on the myocardial cellular milieu ⁵⁷. These additive 539 effects might be especially appealing for the treatment of HF, a disease with a considerable 540 inflammatory component. Although exploratory in nature, the significant effects of GA detected 541 in the small phase 2a clinical trial, and its safety use for ADHF patients, suggest a novel therapeutic 542 potential of GA that should be assessed in larger clinical trials. 543

544

545

546 MATERIALS AND METHODS

547 **Study design - animal models** *Sample size:* For the *in vivo* cardiac injury models, we used a 548 sample size that has previously been shown to yield significant differences in cardiac parameters, 549 such as EF, FS, and scar size. Thus, 5-10 animals were used in each experimental group, depending 550 on the purpose of the experiment and on variation in the observed severity of injuries in individual 551 animals. *Data inclusion/ exclusion criteria:* For the HF experiments, animals that did not show

sufficient injury (EF>45%) or had too severe injury (EF <30%), as measured before the beginning 552 of treatment, were not included in the final analysis. *Replicates:* The exact replicate number for 553 each experiment is provided in the figure legends. Research objectives: The research was designed 554 to examine the effects of GA in MI and HF rodent models and its mechanism of action. Research 555 subjects or units of investigation: We used ICR female mice and Sprague Dawley rats as models 556 557 of cardiac ischemic injury (acute and chronic), as well as primary mouse cardiac cell cultures. *Randomization:* In the HF experiment, animals were paired according to their EF data at 21 days 558 post-LAD ligation and assigned randomly to either GA or control group. *Blinding:* Animals were 559 assigned numbers and echo and histology outcomes were assessed by a blinded investigator. 560

561 **Myocardial infarction.** All animal experiments were approved by the Weizmann Institute of 562 Science Institutional Animal Care and Use Committee (IACUC) and were conducted in 563 compliance with the guidelines and regulations regarding animal research.

Mice: 12-week-old ICR females were sedated with 3% isoflurane (Abbot Laboratories) and then 564 artificially ventilated following tracheal intubation. Experimental myocardial infarction was 565 induced by permanent ligation of the left anterior descending coronary artery as previously 566 described ⁵⁸. Following thoracic wall closure, the mice were injected subcutaneously with 567 buprenorphine (0.066 mg/kg⁻¹) as an analgesic, and warmed until recovery. Rats: 8 weeks old 568 569 Sprague Dawley females were anesthetized with 3% isoflurane, intubated and artificially ventilated. Buprenorphine (0.15 mg/kg SC) was administered before the surgery. Permanent LAD 570 ligation was performed according to the previously published protocol ⁵⁹. The rats were then 571 572 warmed until recovery.

573 Echocardiography parameters. Cardiac function was evaluated by transthoracic 574 echocardiography performed on mice sedated with 2% isoflurane (Abbot Laboratories), using

575 Vevo3100 (VisualSonics). Analysis was performed with the Vevo Lab 3.2.6 software 576 (VisualSonics). Heart rate was continuously monitored using an ECG monitor and remained within 577 350-400 beats/min for the rats and 450-500 beats/min for the mice. EF and FS parameters were 578 measured using the parasternal long axis view (PSLAX), and LVIDd was measured using the M-579 Mode on the parasternal short axis view (SAX).

EV isolation and verification. Mice were subjected to permanent LAD ligation and were treated 580 581 with daily intraperitoneal injections of either GA or mannitol. Animals were sacrificed at 4 dpi, the hearts were perfused with ice-cold PBS, and the LV was isolated and transferred to an 582 Eppendorf tube with 500 µl of sterile cold PBS. The tissue was minced for 30 sec using fine 583 584 scissors on ice and then centrifuged twice at 400 g for 15 min. The supernatant was centrifuged a third time at 20500 g for 45 min. Thereafter, the supernatant was transferred to 1.0 mL PC tubes 585 (Levant Technologies, Cat., 45237) and centrifuged at 100,000 g for 1.5 h at 4°C using Sorvall 586 MX120 Ultracentrifuge, rotor S120-AT2, fixed angle, and resuspended in 60 µl of PBS. EVs were 587 588 verified according to the position statement of the International Society for Extracellular Vesicles, 2018 60. Briefly, a homogenous solution of nanoparticles measuring 30-120 nm in diameter was 589 confirmed by nanoparticle tracking analysis using NanoSight (Malvern Panalytical). 590 591 Subsequently, samples were deposited on glow-discharged formvar-coated copper grids for 592 transmission electron microscopy (TEM) and stained with 2% Uranyl Acetate. Images were taken 593 on a Tecnai 12 TEM (Thermo Fisher Scientific), using a TVIPS F416 CMOS camera. Lastly, proteomic analysis showed enrichment of specific EV markers. 594

595 **EV-mediated reduction in scar area**. Mice were subjected to permanent ligation of LAD and 596 received daily treatment with either 2mg GA, i.p, or an appropriate solvent for 3 days. 597 Subsequently, EVs were isolated from the LV, and used to treat a second cohort of mice using a

single intramyocardial (i.m.) injection following LAD ligation. We validated that GA-derived EVs
 and control-derived EVs were at a similar concentration using NTA (approximately 4 X 10⁹
 particles/mL) in a volume of 50 uL.

EV proteomic analysis. EVs were isolated according to protocol. After ultracentrifugation, pellets 601 were kept at -80°C until analysis. The samples were lysed and digested with trypsin using the S-602 trap method. The resulting peptides were analyzed using nanoflow liquid chromatography 603 604 (nanoAcquity) coupled to high resolution, high mass accuracy mass spectrometry (QE HF). Each sample was analyzed separately in a random order in discovery mode. The raw mass spectrometry 605 data were processed with MetaMorpheus version 0.3.20. Data were searched against the mouse 606 607 UniproKB XML database version 01 2022, with common lab proteins. We applied the spectral 608 recalibration module, G-PTMD module and Search module. Data were normalized and filtered for maximum 1% FDR. Resulting protein table was imported to Perseus. Data were filtered for 609 replication in at least 70% of the replicates in at least one group. Log transformed and missing 610 611 values were imputed from a low, random distribution. ANOVA was used for statistical evaluation. We used the following threshold for significance: q-value <0.05, fold-change >2, and at least 2 612 peptides detected. Gene ontology and pathway analysis was performed using DAVID Analysis 613 Tool, ranked according to log10(control-p-value). 614

615 **Cell culture**. Primary cardiac cultures were isolated from P3 mice using a neonatal dissociation 616 kit (Miltenyi Biotec,130-098-373) and the gentleMACS homogenizer, according to the 617 manufacturer's instructions. Cells were cultured in DMEM/F12 medium (Sigma, D6421) as 618 previously described ⁵⁸. The medium was replaced every other day. For most experiments, cells 619 were seeded in 96-well plates at a cell density of 20,000-30,000 cells/well, or at a density of 2-2.5 620 $\times 10^{5}$ /6 well. Treatment with GA (20-30 µg/ml) or control started 4 days after isolation. Cells from

FUCCI mice (a generous gift from Dr. Mark Sussman, San Diego State University, CA, USA ⁶¹)
 were used to follow CM cell cycle.

Clinical trial. The study was conducted according to the guidelines of the Declaration of Helsinki 623 and approved by the Institutional Review Boards of Hadassah University Medical Center and the 624 Israeli ministry of health (approval number: HMO-093420), and is registered in Israel Ministry of 625 (https://my.health.gov.il/CliniTrials/Pages/MOH 2021-05-Health clinical trials site 626 627 10 009957.aspx). The study was performed in Hadassah Medical Center, Jerusalem, Israel. Basic laboratory work (complete blood count, serum electrolytes, creatinine, NT-proBNP, hs-troponin, 628 CK and liver enzymes) were performed by the core laboratory of the Hadassah Medical Center as 629 part of the routine clinical patient care. Immune panels, consisting of pro- and anti-inflammatory 630 cytokines, were performed in an independent core research laboratory in Sheba Medical Center, 631 Israel. All laboratory work-up was performed by an independent core laboratory that was blind to 632 patient assignment. All patient samples were anonymous and coded. Cytokine levels were 633 measured using Q-PlexTM Human Cytokine Screen (16-Plex), Q110933HU, and Q-PlexTM Human 634 Chemokine (9-Plex), Q120233HU, Quansys Biosciences, UT, USA. 635

Statistical analysis. The results are presented as means \pm SEM and the number of independent biological repeats is indicated for each experiment. Statistical comparisons were carried out by two-tailed Student's *t* test or analysis of variance as appropriate, followed by correction for multiple comparisons using Tukey or Newman-Keuls procedure. Data are presented as mean \pm SEM. Statistical significance was calculated using a two-tailed *t*-test, * *P* < 0.05, ** *P* < 0.01, *** *P* < 0.001.

642

643

644 **References**

- Roger, V. L. Epidemiology of Heart Failure: A Contemporary Perspective. *Circulation research* 128, 1421-1434, doi:10.1161/CIRCRESAHA.121.318172 (2021).
- Westman, P. C. *et al.* Inflammation as a Driver of Adverse Left Ventricular Remodeling After
 Acute Myocardial Infarction. J Am Coll Cardiol 67, 2050-2060,
 doi:10.1016/j.jacc.2016.01.073 (2016).
- Lai, S. L., Marin-Juez, R. & Stainier, D. Y. R. Immune responses in cardiac repair and
 regeneration: a comparative point of view. *Cell Mol Life Sci* 76, 1365-1380,
 doi:10.1007/s00018-018-2995-5 (2019).
- 4 Sattler, S., Fairchild, P., Watt, F. M., Rosenthal, N. & Harding, S. E. The adaptive immune
 response to cardiac injury-the true roadblock to effective regenerative therapies? *NPJ Regen Med* 2, 19, doi:10.1038/s41536-017-0022-3 (2017).
- Gelosa, P., Castiglioni, L., Camera, M. & Sironi, L. Drug repurposing in cardiovascular
 diseases: Opportunity or hopeless dream? *Biochem Pharmacol* 177, 113894,
 doi:10.1016/j.bcp.2020.113894 (2020).
- 659 6 Nosengo, N. Can you teach old drugs new tricks? *Nature* 534, 314-316, doi:10.1038/534314a
 (2016).
- 7 Ziemssen, T., Ashtamker, N., Rubinchick, S., Knappertz, V. & Comi, G. Long-term safety and
 tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple
 sclerosis. *Expert opinion on drug safety* 16, 247-255 (2017).
- 8 Teitelbaum, D., Meshorer, A., Hirshfeld, T., Arnon, R. & Sela, M. Suppression of
 experimental allergic encephalomyelitis by a synthetic polypeptide. *Eur J Immunol* 1, 242248, doi:10.1002/eji.1830010406 (1971).
- Aharoni, R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.
 Autoimmunity reviews 12, 543-553 (2013).
- 669 10 Aharoni, R. Immunomodulation neuroprotection and remyelination-the fundamental
 670 therapeutic effects of glatiramer acetate: a critical review. *Journal of autoimmunity* 54, 81 671 92 (2014).
- Fridkis-Hareli, M. *et al.* Direct binding of myelin basic protein and synthetic copolymer 1 to
 class II major histocompatibility complex molecules on living antigen-presenting cells- specificity and promiscuity. *Proceedings of the National Academy of Sciences* 91, 4872 4876 (1994).
- Aharoni, R., Teitelbaum, D., Arnon, R. & Sela, M. Copolymer 1 acts against the
 immunodominant epitope 82–100 of myelin basic protein by T cell receptor antagonism in
 addition to major histocompatibility complex blocking. *Proceedings of the National Academy of Sciences* 96, 634-639 (1999).
- Weber, M. S. *et al.* Type II monocytes modulate T cell-mediated central nervous system
 autoimmune disease. *Nature medicine* 13, 935 (2007).
- 14 Neuhaus, O. *et al.* Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.
 Proceedings of the National Academy of Sciences 97, 7452-7457 (2000).
- Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I. & Hafler, D. A. Glatiramer acetate
 (Copaxone[®]) induces degenerate, Th2-polarized immune responses in patients with
 multiple sclerosis. *The Journal of clinical investigation* 105, 967-976 (2000).
- 688 16 Aharoni, R. et al. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-

cells in the CNS of mice with relapsing-remitting or chronic EAE. Journal of 689 690 neuroimmunology 225, 100-111 (2010). 17 Aharoni, R., Kayhan, B., Eilam, R., Sela, M. & Arnon, R. Glatiramer acetate-specific T cells 691 692 in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. *Proc Natl Acad Sci U S A* **100**, 14157-14162, doi:10.1073/pnas.2336171100 (2003). 693 18 Aharoni, R. et al. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-694 cells in the CNS of mice with relapsing-remitting or chronic EAE. J Neuroimmunol 225, 695 100-111, doi:10.1016/j.jneuroim.2010.04.022 (2010). 696 19 Aharoni, R., Yussim, A., Sela, M. & Arnon, R. Combined treatment of glatiramer acetate and 697 low doses of immunosuppressive drugs is effective in the prevention of graft rejection. 698 International immunopharmacology 5, 23-32 (2005). 699 20 Aharoni, R. et al. Transplanted myogenic progenitor cells express neuronal markers in the 700 CNS and ameliorate disease in Experimental Autoimmune Encephalomyelitis. Journal of 701 neuroimmunology 215, 73-83 (2009). 702 21 Aharoni, R. et al. Immunomodulatory therapeutic effect of glatiramer acetate on several 703 704 murine models of inflammatory bowel disease. Journal of Pharmacology and 705 Experimental Therapeutics 318, 68-78 (2006). 22 Aharoni, R., Sonego, H., Brenner, O., Eilam, R. & Arnon, R. The therapeutic effect of 706 glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-707 708 inflammatory T-cells. Immunology letters 112, 110-119 (2007). 23 Horani, A. et al. Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of 709 experimental hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 292, G628-638, 710 doi:10.1152/ajpgi.00137.2006 (2007). 711 24 Bassat, E., Perez, D. E. & Tzahor, E. Myocardial Infarction Techniques in Adult Mice. 712 Methods Mol Biol 2158, 3-21, doi:10.1007/978-1-0716-0668-1 1 (2021). 713 714 25 Zerwic, J. J., Rvan, C. J., DeVon, H. A. & Drell, M. J. Treatment seeking for acute myocardial infarction symptoms: differences in delay across sex and race. Nurs Res 52, 159-167 715 (2003). 716 26 Epelman, S., Liu, P. P. & Mann, D. L. Role of innate and adaptive immune mechanisms in 717 718 cardiac injury and repair. Nature reviews. Immunology 15, 117-129, doi:10.1038/nri3800 (2015). 719 720 27 Aharoni, R. Immunomodulation neuroprotection and remyelination - the fundamental 721 therapeutic effects of glatiramer acetate: a critical review. J Autoimmun 54, 81-92, doi:10.1016/j.jaut.2014.05.005 (2014). 722 28 Aharoni, R. et al. Immunomodulatory therapeutic effect of glatiramer acetate on several 723 murine models of inflammatory bowel disease. J Pharmacol Exp Ther 318, 68-78, 724 doi:10.1124/jpet.106.103192 (2006). 725 29 Ma, Y. Role of Neutrophils in Cardiac Injury and Repair Following Myocardial Infarction. 726 727 Cells 10, doi:10.3390/cells10071676 (2021). 30 Santos-Zas, I., Lemarie, J., Tedgui, A. & Ait-Oufella, H. Adaptive Immune Responses 728 Contribute to Post-ischemic Cardiac Remodeling. Front Cardiovasc Med 5, 198, 729 730 doi:10.3389/fcvm.2018.00198 (2018). 31 Puhl, S. L. & Steffens, S. Neutrophils in Post-myocardial Infarction Inflammation: Damage 731 vs. Resolution? Front Cardiovasc Med 6, 25, doi:10.3389/fcvm.2019.00025 (2019). 732 733 32 Grune, J. et al. Neutrophils incite and macrophages avert electrical storm after myocardial infarction. Nat Cardiovasc Res 1, 649-664, doi:10.1038/s44161-022-00094-w (2022). 734

- Averill, M. M., Kerkhoff, C. & Bornfeldt, K. E. S100A8 and S100A9 in cardiovascular
 biology and disease. *Arterioscler Thromb Vasc Biol* 32, 223-229,
 doi:10.1161/ATVBAHA.111.236927 (2012).
- 34 Harhous, Z., Booz, G. W., Ovize, M., Bidaux, G. & Kurdi, M. An Update on the Multifaceted
 Roles of STAT3 in the Heart. *Front Cardiovasc Med* 6, 150, doi:10.3389/fcvm.2019.00150
 (2019).
- I. J., Tan, J., Martino, M. M. & Lui, K. O. Regulatory T-Cells: Potential Regulator of Tissue
 Repair and Regeneration. *Front Immunol* 9, 585, doi:10.3389/fimmu.2018.00585 (2018).
- Jee, Y. *et al.* CD4+ CD25+ regulatory T cells contribute to the therapeutic effects of glatiramer
 acetate in experimental autoimmune encephalomyelitis. *Clinical Immunology* 125, 34-42
 (2007).
- 746 37 Dick, S. A. *et al.* Self-renewing resident cardiac macrophages limit adverse remodeling
 747 following myocardial infarction. *Nat Immunol* 20, 29-39, doi:10.1038/s41590-018-0272-2
 748 (2019).
- 38 Loyer, X. *et al.* Intra-Cardiac Release of Extracellular Vesicles Shapes Inflammation
 Following Myocardial Infarction. *Circulation research* 123, 100-106,
 doi:10.1161/CIRCRESAHA.117.311326 (2018).
- 39 Pezzana, C., Agnely, F., Bochot, A., Siepmann, J. & Menasche, P. Extracellular Vesicles and
 Biomaterial Design: New Therapies for Cardiac Repair. *Trends Mol Med* 27, 231-247,
 doi:10.1016/j.molmed.2020.10.006 (2021).
- 40 Yadid, M. *et al.* Endothelial extracellular vesicles contain protective proteins and rescue
 ischemia-reperfusion injury in a human heart-on-chip. *Sci Transl Med* 12,
 doi:10.1126/scitranslmed.aax8005 (2020).
- Piamsiri, C., Maneechote, C., Siri-Angkul, N., Chattipakorn, S. C. & Chattipakorn, N.
 Targeting necroptosis as therapeutic potential in chronic myocardial infarction. *J Biomed Sci* 28, 25, doi:10.1186/s12929-021-00722-w (2021).
- 42 Tallquist, M. D. & Molkentin, J. D. Redefining the identity of cardiac fibroblasts. *Nat Rev Cardiol* 14, 484-491, doi:10.1038/nrcardio.2017.57 (2017).
- Talman, V. & Kivela, R. Cardiomyocyte-Endothelial Cell Interactions in Cardiac Remodeling
 and Regeneration. *Front Cardiovasc Med* 5, 101, doi:10.3389/fcvm.2018.00101 (2018).
- 44 Liu, J. *et al.* T cell independent mechanism for copolymer-1-induced neuroprotection. *Eur J Immunol* 37, 3143-3154, doi:10.1002/eji.200737398 (2007).
- 45 Narmoneva, D. A., Vukmirovic, R., Davis, M. E., Kamm, R. D. & Lee, R. T. Endothelial cells
 promote cardiac myocyte survival and spatial reorganization: implications for cardiac
 regeneration. *Circulation* 110, 962-968, doi:10.1161/01.CIR.0000140667.37070.07
 (2004).
- 46 Murphy, S. P., Kakkar, R., McCarthy, C. P. & Januzzi, J. L., Jr. Inflammation in Heart Failure:
 JACC State-of-the-Art Review. J Am Coll Cardiol 75, 1324-1340, doi:10.1016/j.jacc.2020.01.014 (2020).
- 47 Zile, M. R. *et al.* Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic
 Peptide in Patients With Heart Failure. *J Am Coll Cardiol* 68, 2425-2436,
 doi:10.1016/j.jacc.2016.09.931 (2016).
- 48 Julier, Z., Park, A. J., Briquez, P. S. & Martino, M. M. Promoting tissue regeneration by
 modulating the immune system. *Acta Biomater* 53, 13-28,
 doi:10.1016/j.actbio.2017.01.056 (2017).
- 780 49 Vagnozzi, R. J. et al. An acute immune response underlies the benefit of cardiac stem cell

therapy. *Nature* **577**, 405-409, doi:10.1038/s41586-019-1802-2 (2020).

781

- 50 Miettinen, K. H. *et al.* Prognostic role of pro- and anti-inflammatory cytokines and their
 polymorphisms in acute decompensated heart failure. *Eur J Heart Fail* 10, 396-403,
 doi:10.1016/j.ejheart.2008.02.008 (2008).
- 51 Jensen, J. *et al.* Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. *Clin Res Cardiol* 99, 445-452, doi:10.1007/s00392-010-0140-z (2010).
- Ziemssen, T., Ashtamker, N., Rubinchick, S., Knappertz, V. & Comi, G. Long-term safety and
 tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple
 sclerosis. *Expert Opin Drug Saf* 16, 247-255, doi:10.1080/14740338.2017.1274728
 (2017).
- Ford, C. *et al.* Continuous long-term immunomodulatory therapy in relapsing multiple
 sclerosis: results from the 15-year analysis of the US prospective open-label study of
 glatiramer acetate. *Mult Scler* 16, 342-350, doi:10.1177/1352458509358088 (2010).
- 54 Miller, A., Spada, V., Beerkircher, D. & Kreitman, R. R. Long-term (up to 22 years), openlabel, compassionate-use study of glatiramer acetate in relapsing-remitting multiple
 sclerosis. *Mult Scler* 14, 494-499, doi:10.1177/1352458507085029 (2008).
- 55 Braenne, I. *et al.* Genomic correlates of glatiramer acetate adverse cardiovascular effects lead
 to a novel locus mediating coronary risk. *PLoS One* 12, e0182999,
 doi:10.1371/journal.pone.0182999 (2017).
- 56 Januzzi, J. L., Jr. *et al.* Prognostic Importance of NT-proBNP and Effect of Empagliflozin in
 the EMPEROR-Reduced Trial. J Am Coll Cardiol 78, 1321-1332,
 doi:10.1016/j.jacc.2021.07.046 (2021).
- 57 Tzahor, E. & Dimmeler, S. A coalition to heal-the impact of the cardiac microenvironment.
 Science 377, eabm4443, doi:10.1126/science.abm4443 (2022).
- 58 Bassat, E. *et al.* The extracellular matrix protein agrin promotes heart regeneration in mice.
 Nature 547, 179-184, doi:10.1038/nature22978 (2017).
- 59 Wu, Y., Yin, X., Wijaya, C., Huang, M. H. & McConnell, B. K. Acute myocardial infarction
 in rats. *J Vis Exp*, doi:10.3791/2464 (2011).
- 60 Thery, C. *et al.* Minimal information for studies of extracellular vesicles 2018 (MISEV2018):
 a position statement of the International Society for Extracellular Vesicles and update of
 the MISEV2014 guidelines. *J Extracell Vesicles* 7, 1535750,
 doi:10.1080/20013078.2018.1535750 (2018).
- Alvarez, R., Jr. *et al.* Cardiomyocyte cell cycle dynamics and proliferation revealed through
 cardiac-specific transgenesis of fluorescent ubiquitinated cell cycle indicator (FUCCI). *Journal of molecular and cellular cardiology* 127, 154-164,
 doi:10.1016/j.yjmcc.2018.12.007 (2019).
- Redfors, B., Shao, Y. & Omerovic, E. Myocardial infarct size and area at risk assessment in
 mice. *Exp Clin Cardiol* 17, 268-272 (2012).
- Ali, M. A., Kandasamy, A. D., Fan, X. & Schulz, R. Hydrogen peroxide-induced necrotic cell
 death in cardiomyocytes is independent of matrix metalloproteinase-2. *Toxicol In Vitro* 27, 1686-1692, doi:10.1016/j.tiv.2013.04.013 (2013).
- 64 Gavert, N. *et al.* Ex vivo organotypic cultures for synergistic therapy prioritization identify 823 patient-specific responses to combined MEK and Src inhibition in colorectal cancer. *Nat* 824 *Cancer* **3**, 219-231, doi:10.1038/s43018-021-00325-2 (2022).
- Sarig, R., Baruchi, Z., Fuchs, O., Nudel, U. & Yaffe, D. Regeneration and transdifferentiation
 potential of muscle-derived stem cells propagated as myospheres. *Stem Cells* 24, 1769-

827	1778 (2006).

828

829 Acknowledgments

830 We thank Ishai Sher from the Graphic Department at Weizmann Institute for excellent graphic

- assistance; Marina Cohen from the Histology unit at Weizmann Institute; Yishai Levin and Corine
- 832 Katina from the Proteomic Unit of the Grand Israel National Center for Personalized Medicine, at
- 833 Weizmann Institute; Galina Levin, Larisa Kogan and Lilian Abu-Heichel for coordinating the
- 834 clinical trial in Hadassah Medical Center; Oliana Vazhgovsky for coordinating the biopsies
- transfer from Sheba Medical Center.

836

837 Funding:


- 838 The study was supported by the following funding sources:
- European Research Council, ERC AdG grant no. 788194, CardHeal (E.T)
- 840 ERC-PoC no. 899224, ReDHeaD (E.T)
- EU Horizon 2020 Research and Innovation Programme REANIMA

842 Author contributions:

843	Conceptualization: R.S, E.T, G.A, O.A, K.U
844	Methodology: R.S, E.T, G.A, O.A, R.A, K.U, Ru.A, Ri.A
845	Investigation: G.A, J.E, K.U, H.B, R.S, S.M, D.L, D.K, U.K, D.N, M.A, D.M, T.S,
846	L.Z, Z.P
847	Funding acquisition: E.T
848	Supervision: E.T, R.S
849	Writing – original draft: E.T, R.S, G.A

850	Writing – review & editing: O.A, R.A
851	Competing interests: The authors vouch no competing interests.
852	Data and materials availability: Raw data of proteomic analysis will be provided at later
853	stages.
854	
855	
856	
857	
858	
859	
860	
861	
862	
863	
864	
865	
866	
867	
868	
869	


870 FIGURES



872 Figure 1: Glatiramer acetate improves mouse cardiac function after myocardial infarction.

A, A scheme of the experimental procedure. Mice were divided into two groups receiving either 873 GA (2 mg/animal/day) or control (PBS / mannitol) by daily IP injections, from day 0 (day of MI) 874 up to 14 days post-MI. Echo measurements were performed at baseline (2 days before MI) and at 875 2-, 14- and 35-days post-MI. Histological analysis was performed postmortem. B,C, 876 877 Echocardiographic measurements of ejection fraction (EF, \mathbf{B}) and fractional shortening (FS, \mathbf{c}) at baseline, 2 days and 35 days after panels). The percent reduction in EF or FS is shown on the right 878 $(n_{control} = 13, n_{GA} = 20)$. D, Masson's trichrome staining of heart sections derived from 879 880 representative PBS- (Ctrl, top) or GA-treated hearts (bottom). E, Left: Mean percentage of scar area in sections from GA- or control-treated hearts 35 days after MI. Right: Scar stratification 881 according to size reveals that large scars (>30% of LV) were found only in the control group. F, 882 representative sections of control (upper row) and GA-treated (lower row) hearts, showing well 883 perfused myocardium (black), IAAR (dashed vellow line) and IZ (dashed white line). G, 884 Quantification of % IAAR/LV showing no significant differences between the groups, while % 885 IZ/IAAR and %BZ/IAAR demonstrate a significant reduction in IZ following GA treatment and 886 increase in BZ, suggesting myocardial protection ($n_{GA} = 4$, $n_{control} = 3$). IAAR = ischemic area-at-887 888 risk, IZ = infarct zone, BZ = border zone. H, A wide temporal therapeutic window for GA is shown by echo measurements of EF (upper) and FS (lower) in animals treated with PBS (control) or GA 889 at the day of injury, 24- or 48-hours post-MI. $n_{control} = 9$, $n_{GA/t0} = 16$, $n_{GA/24h} = 7$, $n_{GA/48h} = 5$. 890

891



892

894 Figure 2: GA treatment promotes a pro-reparative immune phenotype

A, Experimental design. Sample size -1 dpi ($n_{GA} = 1$, $n_{Control} = 1$), 4 dpi ($n_{GA} = 2$, $n_{Control} = 2$). B, 895 EF values at baseline and 3 dpi, demonstrating a cardiac protective effect induced by GA treatment. 896 C, Dimensional reduction with UMAP. D, Frequency plots of specific cell types according to days. 897 E, Neutrophilic cluster, F, Heatmap of DEG between GA and control at 1 dpi. Adjusted P-value 898 <0.05. G, A violin plot for canonical markers for neutrophil activation. H, IPA performed on DEG 899 900 of neutrophil cluster at 1 dpi. I, FACS analysis measuring the percentage of myeloid cells and neutrophils in control versus GA-treated mice 24h after MI ($n_{control} = 5$, $n_{GA} = 6$). J, Levels of pro-901 inflammatory mediators IL- α and CCL-2 were measured 24h post-MI in serum by ELISA. Levels 902 903 are shown as fold-change from uninjured mice. $n_{GA} = 4$, $n_{mannitol} = 4$, $n_{sham} = 3$. K, highlights of T cells and Timd4+ resident macrophages. L, IPA performed on DEG of T cells and Timd4+ 904 macrophages on respective clusters of CD45+ cell subset (adjusted P value <0.05). M, upper 905 *panel*: FACS analysis of Timd4+ macrophages in GA-treated hearts 4 dpi $(n_{mannitol} = 5, n_{GA} = 4)$ 906 and Foxp3+ Tregs in GA-treated hearts 7 dpi (n = 5 for each group). Lower panel: Representative 907 heart sections derived from GA- or PBS-treated mice 7 dpi that were co-immunostained with anti-908 CD3 and anti-Foxp3. Scale bars: 60µm. 909

910

911


912

913

914


915

916



939 Figure 3: The protective effect of glatiramer acetate is mediated by extracellular vesicles.

A, Representative M-mode echocardiography images, at 3 dpi. B, Analysis of echocardiographic 940 systolic parameters. C, PCA of proteomic data. D, Heatmap of differentially expressed proteins 941 (n=3 in each group). E, Gene ontology terms and pathway analysis. Arrow points to extracellular 942 exosomes pathway. F, A graphical illustration of EV experiments (n=16). G, Representative M-943 944 mode echocardiography images, at 3 dpi. H, EF measurements (left), comparing the three experimental groups at baseline and 3 dpi. The right panel shows the change in EF as a fold-change 945 946 from baseline levels. I, Masson Trichrome representative cardiac sections (left) and IF images (right) demonstrate smaller infarcts with large areas of viable myocardium, as well as higher 947 density of α SMA+ blood vessels (arrowheads) in mice treated with GA-derived EVs. Scale bars: 948 left panels, 750µm; right panels, 120µm. J,K, Analysis of infarct size (n=15) (J), and blood vessel 949 950 density (n=6) (K) at 4 dpi. L, Proteomic analysis of cardiac EVs. Unsupervised PCA showing 3 distinct clusters of the experimental groups. M, ANOVA results of differentially expressed 951 proteins between GA-derived and control-derived EVs. N, Gene ontology terms and pathway 952 analysis, ranked according to -log10(corrected-p-value). O, targeted heatmap of individual 953 proteins comprising key differentially changed pathways. Statistical significance was calculated 954 using a two-tailed *t*-test, or ANOVA with Tukey's correction for multiple comparisons, as 955 appropriate. 956




957





A, Representative heart sections showing scar analysis (left) and TUNEL assay in the border-zone 24h after injury. Scale bars: middle panels, 200 μ m; right panels, 400 μ m. **B**, Higher magnifications showing TUNEL positive cells in CMs. Scale bar: 75 μ m. **C,D**, Quantification of percentage of apoptotic nuclei in CMs at 24h (C) and 96h (D) post-MI (n_{control} =4; n_{GA} = 3, an average of 458 cells were counted for each group). **E**, Representative heart sections showing scar analysis (left) and TUNEL assay in the border-zone 96h after injury. Scale bars: 200 μ m. **F**, Representative heart

965	sections derived from control and GA-treated hearts, stained with anti-vimentin (24h) or anti-
966	vimentin with anti-Ki67 (96h) in the border-zone. Scale bars: left, 400 μ m; right, 120 μ m. G,
967	Quantification of proliferating CFs at 4dpi ($n_{GA} = 4$, $n_{control} = 3$). 1658 and 736 cells were counted
968	for GA and PBS, respectively. H, Quantification of capillaries observed in the injured area,
969	normalized to the scar area ($n_{PBS} = 5$, $n_{GA} = 4$). I, Representative heart sections derived from GA-
970	or PBS- treated mice at 14 dpi, showing capillary formation in the scar area. Right panels show
971	higher magnification of the left panels. Scale bars: left panels, 750 μ m; right panels, 150 μ m. J,
972	Representative heart sections derived from GA- or PBS-treated mice at 14 dpi, showing scar area
973	(left panels), and SMA+ blood vessels (right panels). Scale bars: 120µm. K, Quantification of
974	blood vessels observed in the injured area, normalized to the scar area (n=3 for each group).










981	CMs between the two groups (right) (n = 5, 2500 cells). Scale bars: 300 μ m. D , P3 cultures were
982	treated with FITC-GA stained with the indicated antibodies. Scale bars: upper left, 300 μ m; lower
983	left and right panels, 150 μ m. E , EVOC treated with FITC-GA show its accumulation in interstitial
984	cells. F, Representative fields show a large colony of ECs in GA-treated cultures, whereas in
985	control cultures CD31+ cells were dispersed. Scale bars: 300 μ m. G, Quantification of
986	proliferating ECs (n=3 for each group, 678 and 1704 cells for the control and GA, respectively).
987	H, IF stain of P3 cultures 14 days following treatment with GA. Scale bars: left, 300 μ m; right,


988 150 μm. I, qRT-PCR analysis of CD31 and cTnI in the cultures described in H.




990 Figure 6: Transient treatment with glatiramer acetate improves heart function in a rat model



992	A, A scheme of the experimental procedure. B, Representative echocardiographic loops of short
993	axis view at baseline (left, <u>https://youtu.be/k58RMQJ1ed4</u> and 21 dpi (right,
994	https://youtu.be/6m3PJscTPJc) C, Relative mRNA expression of Nppb (n=3, left panel), and
995	echocardiographic measurement of LVID in diastole at baseline and 21 dpi (n=23, right panel). D ,
996	Representative images using the M-Mode configuration. E,F, Echocardiographic measurements
997	of EF (E) and FS (F) parameters in hearts that were treated with GA compared to control hearts.
998	Grey area marks the period of injections. G,H, Graphs showing the individual (left) and mean
999	(right) differences in EF (G) and FS (H) parameters between 21- and 120-days post-injury. I, The
1000	mean % difference in LVID in diastole at 120 dpi between animals treated with control (left, red)
1001	and GA (right, blue) ($n_{control} = 11$, $n_{GA} = 12$). J, Echocardiographic measurements of the LV volume
1002	in systole ($n_{control} = 11$, $n_{GA} = 12$). K, representative images of histological sections comparing
1003	interstitial fibrosis at the beginning of treatment (21d) and at end-point (120d), together with the
1004	quantification (right) ($n_{21d} = 9$, $n_{control} = 5$, $n_{GA} = 6$).







A,B, Trial design. Patients admitted to the hospital with ADHF were screened over 48h. Eligible
patients were assigned to receive only GDMT or GDMT with GA as an add-on therapy for 14

1011 days. Repeat clinical follow up and blood sample analysis of cytokines and cardiac biomarkers were performed at the indicated time points. C, Baseline values of parameters associated with the 1012 primary (selected cytokines) and secondary (NT-proBNP) endpoints. Continuous variables are 1013 presented as median and interquartile range (IQR), discrete variables as proportions. **D**, Primary 1014 1015 endpoint - GA blunts the cytokine surge in patients with ADHF. A logarithmic scale of the mean 1016 pooled results for each cytokine at days 2 and 14, normalized to baseline levels. A significant general silencing of the cytokine surge is detected in the GA-treated group of patients. E, Separate 1017 values of representative cytokines showing significant changes the GA-treated group. F, 1018 1019 Secondary endpoint - GA treatment significantly reduced serum levels of NT-proBNP, the levels of which are presented as fold-change from baseline (left) and as raw values on a logarithmic scale 1020 1021 (right). G, A scatter plot showing the fold-change in NT-proBNP levels as a function of different 1022 serum cytokines, transformed on a logarithmic scale. The GA-treated group (in blue) is clustered on the bottom left, reflecting low levels of both cytokines and NT-proBNP, as opposed to control 1023 group (in red), clustered on the top right, reflecting high inflammation and NT-proBNP levels. 1024

1025

- 1026 List of Supplementary Materials
- 1027 Supplementary Materials and Methods
- 1028 Fig. S1 to S10
- 1029 Supplementary Tables 1-2

1030

1031

1032

1034 Supplementary Materials

1035

1036 Supplementary materials and methods

Glatiramer acetate. Two types of GA were used for the experiments: either powder or Copaxone 1037 syringes (both from Teva), with proper controls for each type. PBS was used to dissolve the 1038 powder, whereas mannitol was the solvent of Copaxone syringes. The potency of the two GA 1039 1040 preparations was very similar in all the described experiments. For the *in vivo* experiment, we used 1041 a well-established concentration of $2 \text{ mg}/100 \mu \text{l}$, which was shown to be effective for the treatment of EAE mice ^{9,10}. The concentration used for the *in vitro* experiments was 20-30 µg/ml. A Protein 1042 FITC Labeling Kit (EZLabelTM, K832-5, BioVision Inc., USA) was used to produce a FITC-1043 conjugated GA, according to the manufacturer's instructions. 1044

Scar quantification. Scarred tissue was quantified by performing Masson's trichrome staining on serial cardiac sections spanning the entire left ventricle using ImageJ. The area of scar (blue) and LV were calculated and summed from all sections in order to obtain true scar volume normalized to LV myocardial volume.

1049 **Blood vessel and endothelial cell density**. Capillary and blood vessel density were calculated by 1050 measuring CD31+ area and counting α SMA+ blood vessels in scar tissue, respectively, normalized 1051 to scar area. Area measurements were performed using ImageJ.

Assessment of ischemic area-at-risk and infarct zone. Assessment of IAAR was performed as previously published 62 with modifications. Briefly, At the 4th day after permanent LAD ligation, animals were anesthetized using CO₂ inhalation. Demarcation of ischemic area-at-risk was achieved by performing *in situ* antegrade perfusion using 8 mL of black dye through ventricular apical canulation. Subsequently, hearts was excised from the chest, washed twice in ice-cold PBS

and transferred to -20° c for 8 minutes. Hearts were then axially sectioned using a razor blade, at 200 µm intervals. For delineating infarct zone, the myocardial sections were subsequently incubated at room temperature in 2% triphenyltetrazolium chloride (Sigma-Aldrich, T8877) for 10 minutes, after which the sections were washed twice with PBS. Sections were imaged using a stereomicroscope (Carl Zeiss Stemi 305cam Binocular). Quantification of ARR and IZ were performed using ImageJ, and normalized to LV where appropriate.

1063 Sample and libraries preparation for scRNA-seq. Single-cell RNA-seq libraries were prepared 1064 at the Crown Genomics Institute of the Nancy and Stephen Grand Israel National Center for 1065 Personalized Medicine, Weizmann Institute of Science using the 10X Genomics technology. 1066 Tissue was dissociated into single-cell suspension using a neonatal dissociation kit (Miltenyi 1067 Biotec, 130-098-373) and the gentleMACS homogenizer, according to the manufacturer's 1068 instructions. Briefly, animals were sacrificed, and the hearts were perfused in situ using ice-cold PBS solution. Subsequently the hearts were excised from the body and washed twice in PBS. The 1069 atria and right ventricle were removed to enrich for LV tissue. The LV-enriched tissue was minced 1070 1071 to small pieces using fine scissors. The tissue was transferred to a gentleMACS C-tube (130-093-1072 237) and dissociation was carried according to the protocol. Enrichment for CD45+ cells was 1073 achieved using CD45 MicroBeads enrichment protocol (Miltenyi Biotec, 130-052-301). Briefly, CD45+ cells were magnetically labeled with CD45 MicroBeads. Positive selection of immune 1074 cells was achieved by mounting the labeled suspension on a MACS Column, placed in a magnetic 1075 field of a MACS Separator. Cells were counted and viability was assessed using trypan blue and a 1076 hemocytometer. Cells were diluted in PBS + 0.04% BSA to a final concentration of 1000 cells/ul 1077 1078 and immediately processed with the Chromium Next GEM Single Cell 3' v3.1 kit, according to 1079 the manufacturer protocol. Final libraries were quantified by qPCR with the NEB-next Library

Quant Kit (New Englnad Biolabs), as well as with Qubit and TapeStation. Sequencing was done
on a Nova-Seq6000 using SP, 100 cycles kit mode allocating 800M reads in total (Illumina). Fastq
files were generated by the usage of bcl2fastq v2.20.0.422.

1083 Bioinformatic analysis

CellRanger pipeline (Zheng et al., 2017) (v7.0.1, 10× Genomics) with default settings was used 1084 for alignment (mm10 reference genome, 2020-A version, downloaded from 10× Genomics 1085 website), filtering, barcode counting and UMI (Unique Molecular Identifier) counting. The R 1086 Seurat package (Satija et al., 2015) (v4.0.4) was used for quality control, dimensionality reduction, 1087 1088 visualization, and analysis. Low-quality cells were excluded based on the following criteria: having fewer than 250 genes, fewer than 500 UMIs, and exceeding 4 MAD (median absolute 1089 1090 deviation) the median for genes, UMIs, and mitochondrial reads. Additionally, genes expressed in 1091 less than 10 cells were eliminated from the analysis. After implementing these quality control 1092 measures, a total of 49,369 cells (from all samples) and 21,031 genes were retained for further 1093 analysis (control dpi 1: 3016, GA dpi 1: 3537, control dpi 4: 24431, GA dpi 4: 18,385).

Merged counts matrix was log-normalized using the NormalizeData function. The 2,000 highly variable genes were identified using the FindVariableFeatures function with the 'vst' method. Data was scaled with the ScaleData function. Principal component analysis (PCA) was performed. Seurat's unsupervised graph-based clustering and uniform manifold approximation (UMAP) were conducted on the projected principal component (PC) space.

1099 Marker genes for each cluster were determined with the non-parametric Wilcoxon rank sum test 1100 by FindAllMarkers function. Those with a logFC > 0.5 and expressed in at least 50% of the cells 1101 were selected as significant marker genes. Cell types were identified based on the expression of 1102 classic marker genes. Cells were represented by a total of 19 clusters including monocytes and

macrophages (Cd68+Itgam+), neutrophils (S100a9+S100a8+), T cells (Cd3e+Cd3d+), B cells (Cd79aMs4a1+), endothelial cells (Kdr+Pecam1+), fibroblasts (Col1a1+Dcn+), myofibroblasts (Col1a1+Postn+), pericytes (Rgs5+Abcc9+) and smooth muscle cells (Acta2+Myh11+) (Fig. 2C). Visualization used Seurat's FeaturePlot, DotPlot and VlnPlot functions.

FindMarkers was used to identify DE genes between different clusters. Those with a p_val_adj <
0.05 were considered to be significant and taken for furher analysis using IPA (Ingenuity®
Systems, www.ingenuity.com) or DAVID analysis tool.

Bulk proteomic analysis. Cardiac samples of proteomic analysis were processed as previously 1110 published ⁵⁸. Hearts were removed 4 days post-MI and briefly perfused with ice-cold PBS. The 1111 1112 left ventricle was dissected and snap-frozen in liquid nitrogen. Samples were crushed to a fine powder, intermittently maintaining nitrogen cooling, and transferred into a lysis buffer consisting 1113 of 5% SDS and 50 mM Tris (pH 7.4) for thorough homogenization using a drill. The samples were 1114 centrifuged at 5000 g for 15 sec and boiled at 96°C for 15 min. After further centrifugation at 1115 1116 maximal speed for 2 min, the supernatant was collected, and protein concentrations were quantified by BCA assay (Thermo Fisher, 23225). For LC-MS and data processing, samples were 1117 lysed with urea and subjected to in-solution tryptic digestion, followed by a desalting step. The 1118 1119 resulting peptides were analyzed using Waters HSS-T3 column on nanoflow liquid 1120 chromatography (nanoAcquity) coupled to high resolution, high mass accuracy mass spectrometry 1121 (Fusion Lumos). Thresholds used were p-value <0.05, fold-change >2, and at least 2 peptides 1122 detected on mass spectrometry. Gene ontology (GO) terms and pathway analysis performed using 1123 DAVID Analysis Tool.

1124 **ROS assay**. ROS assays were performed as previously published with modifications 63 . P3 primary 1125 cultures were treated with either 30 μ g/ml GA, PBS, or conditioned media for 3 days. On the third

1126 day of treatment, the cells were challenged with 1 μ M H₂O₂ (Sigma, 7722-84-1) or a similar 1127 volume of PBS for 2 h, after which the wells were washed twice with warm PBS. For DAPI 1128 exclusion assay, 0.5 μ g/mL DAPI (Sigma, Cat. no. D9542) was added to the media for 10 min. 1129 Cells were subsequently washed with PBS and fixated in 4% PFA followed by 1130 immunofluorescence staining.

1131 **RT–qPCR**. RNA from whole hearts or cultured cells was isolated using a NucleoSpin kit 1132 (Machery Nagel, 740955.50) according to the manufacturer's instructions. A High capacity cDNA 1133 reverse transcription kit (Applied Biosystems, 4374966) was used to reverse transcribe 1 μ g of 1134 purified RNA according to the manufacturer's instructions. The quantitative PCR reactions were 1135 performed using a Fast SYBR Green PCR master mix (Thermo Fischer Scientific, 4385614) on a 1136 StepOnePlus Real-Time PCR system (Applied Biosystems). Values for specific genes were 1137 normalized to *Hprt* housekeeping control.

1138 **TUNEL assay.** Apoptotic cell death of both cell cultures and cardiac sections was measured using 1139 the ApopTag[®] Red *In Situ* Apoptosis Detection Kit (S7165, Merck), according to the 1140 manufacturer's instructions. Staurosporine (1 μ M, Sigma-Aldrich) or DMSO were added to 1141 cardiac cultures together with either 20 μ g/ml GA or PBS for 18 h.

1142 **Ex vivo organ cultures (EVOC).** EVOC were prepared according to Gavert *et al.*, ⁶⁴, with 1143 modification for heart samples. Adult mice were euthanized, and their hearts were placed in ice-1144 cold PBS. The fresh heart tissues were then filled with a 3.5% (w/v) low melting agarose 1145 preparation media sliced into 280-µm-thick slices using a vibratome (Leica VT1000 S). Heart 1146 slices were cultured in growth media with GA or Mannitol for 48h, followed by treatment with 0.1 1147 µM H₂O₂ for 4h. Slices were fixed, embedded in paraffin, and 5 µm slices were used for TUNEL 1148 assay and IF staining.

Cytokine measurements. Plasma and tissue protein levels were measured using a multiplex 1149 1150 ELISA kit (mouse cytokine array GSM-CYT-1, RayBiotech, GA, USA) according to the 1151 manufacturer's protocol. In brief, blood was drawn from the retro-orbital venous plexus using glass pipettes pre-washed with 500 U/ml of heparin. Samples were centrifuged at 1200 rpm for 10 1152 min at 4°C and plasma was transferred into new tubes and kept at -80°C. For tissue protein 1153 1154 analysis, LV tissue was dissected from the whole heart and snap-frozen in liquid nitrogen. Frozen samples were crushed with a mortar and pestle and subsequently homogenized with a drill. Total 1155 1156 cell lysates were isolated using RIPA buffer supplemented with 1:100 protease (Sigma, P8340) 1157 and 1:100 phosphatase inhibitor cocktails (Sigma, P5726 and P0044). Protein concentrations were measured by BCA assay (Thermo Fisher, 23225). To each well, 750 µg/mL of tissue protein 1158 extract or 1:2 diluted plasma were added and incubated overnight at 4°C with blocking solution. 1159 On the following day, the samples were washed and incubated with biotinylated antibody cocktail 1160 1161 and a secondary Cy3 equivalent dye-streptavidin. The slides were read by the RayBiotech array 1162 scanning service and data were analyzed using Piezoarray Software, version 1.1.0.0016.

EV-enriched serum from patients. Enrichment for human EVs was performed from patients' sera using similar protocols. Subsequently, the sera were analyzed using the standard methods for EV detection: NTA, EM and verification of EV-specific markers using mass spectrometry.

Bulk RNA-seq. For RNA-seq, GA- and control-treated hearts were collected 24 h after MI, and RNA samples were purified using the miRNeasy kit (1038703, Qiagen) according to the manufacturer's instructions. Sequencing libraries were prepared using the RNA-seq protocol of the Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM), Weizmann Institute of Science. Single-end short reads were sequenced on Illumina NextSeq machine. Sequencing libraries were constructed with barcodes to allow multiplexing of the

samples, yielding a median of ~ 25 million single-end reads per sample. Briefly, total RNA was 1172 1173 fragmented followed by reverse transcription and second-strand cDNA synthesis. The double-1174 strand cDNA was subjected to end repair, A base addition, adapter ligation and PCR amplification to create libraries. Libraries were evaluated by Qubit and TapeStation. For RNA analysis, adapters 1175 were trimmed using the cutadapt tool. Resulting reads shorter than 30 bp were discarded. Reads 1176 1177 were mapped to the *Mus musculus* reference genome GRCm38 using STAR, supplied with gene annotations downloaded from Ensembl. with EndToEnd 1178 option and outFilterMismatchNoverLmax set to 0.04. Expression levels for each gene were quantified using 1179 1180 htseq-count, using the gtf above. Differentially expressed genes were identified using DESeq2 with the betaPrior, cooksCutoff and independentFiltering parameters set to False. Raw p-values 1181 were adjusted for multiple testing using the Benjamini and Hochberg procedure. Pipeline was run 1182 using snakemake. 1183

Human cardiac cultures. Cardiac biopsy specimens were obtained from patients with a diagnosis of tetralogy of Fallot (TOF), undergoing an open-heart surgery. Tissue explants were kept on ice until processed and were mechanically minced into 1-mm³ pieces. The cardiac human cells were isolated using a neonatal dissociation kit (Miltenyi Biotec,130-098-373) and the gentleMACS homogenizer, according to the manufacturer's instructions. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Boards of Sheba Medical Center.

Immunofluorescence staining. *Tissue cultures:* cells were fixed with 4% PFA in PBS for 10 min and permeabilized with 0.2% Triton X-100 in PBS for 5 min, followed by blocking with PBS containing 0.1% Triton X-100 and 3% bovine serum albumin for 1 h at room temperature.

Immunostaining was performed as previously described ⁵⁸. *Cardiac sections:* paraffin-embedded 1194 hearts were sectioned, deparaffinized and stained as above with the addition of an antigen retrieval 1195 step that was performed in 10 mM citric acid, (pH 6.0) or 0.1 M Tris-EDTA buffer (pH 9.0). 1196 Images were obtained with a Nikon Eclipse Ti2 fluorescent microscope with the Nikon's NIS-1197 Elements software. Primary antibodies: anti-pHistone 3 (pH3,ab47297 ABCAM 1:1000), anti-1198 1199 Ki67 (Cell Marque #275R, 1:200), anti-cTnT (Abcam, ab33589, 1:200 or CT3 hybridoma product, DSHB by Lin, J.J.-C., 1:10), anti-cTnI (Abcam, ab47003, 1:200 or TI-4 hybridoma product, DSHB 1200 1201 by Schiaffino, S., 1:10), anti-CD31 (Abcam, ab28364, 1:200), anti-Vimentin (Abcam, ab24525, 1202 1:200). SMA (Sigma, A2547, 1:400), anti-Foxp3 (Invitrogen, FJK-16S, 1:100), anti-CD3 (Abcam, ab16669, 1:150). 1203

FACS. Hearts were perfused with 10 ml of ice-cold PBS and left ventricles were dissected and 1204 digested in RPMI containing Collagenase-I (Sigma, 450 U/ml), Collagenase-XI (Sigma, 1205 120U/ml), Hyaluronidase (Sigma, 60 U/ml) and DNase-I (Sigma, 10 mg/ml) at 37°C for 1 h, while 1206 1207 agitated at 200 rpm. Digested materials were passed through a 120-µm metal mesh into 12 ml PBS and pelleted by cooled centrifugation (4°C, 1400 rpm, 5 min). Supernatant was removed and the 1208 pellet was resuspended in 3 ml of MACS buffer (2% FBS, 1 mM EDTA in PBS), followed by 1209 1210 additional centrifugation (4°C, 1400 rpm, 5 min). Samples were blocked in 50 µl of anti-CD16/32 1211 antibodies (clone: 93, 1:200) for 20 min at 4°C, resuspended in 3 ml MACS buffer and centrifuged 1212 (4°C, 1400 rpm, 5 min). Cells were incubated in antibody mixture (50 μ l) in MACS buffer for 20 1213 min at 4°. Samples were washed in 3 ml MACS buffer containing DAPI (0.5 µg/mL) and 1214 centrifuged (4°C, 1400 rpm, 5 min). Single-cell suspension was resuspended in 0.5 ml of MACS 1215 buffer and filtered through 40-µm mesh prior to FACS analysis by Fortessa (BD Biosciences, BD 1216 Diva Software). For intracellular staining, cells were processed as described above with the


following changes: after primary antibody incubation, cells were washed in MACS buffer and 1217 centrifuged (4°C, 1400 rpm, 5 min), followed by fixation using 1 mL of True-Nuclear[™] 1218 (BioLegend, cat# 424401) for 18h at 4°C. Cells were processed further according to the True-1219 Nuclear[™] manufacturer protocol. Prior to FACS analysis, cells were resuspended in 0.5 ml MACS 1220 buffer. Data were analyzed using the FlowJo (v10.6.2) software. *Antibodies* (all from BioLegend): 1221 1222 CD45 (clone: 30-F11, 1:100), CD11b (clone: M1/70, 1:200), CD4 (clone: GK1.5, 1:100), TCRb (clone: H57-597, 1:100), FOXP3 (clone: MF-14, 1:100), LY6G (clone: 1A8, 1:100), LY6C (clone: 1223 HK1.4, 1:100), GR1 (Ly6C+, Ly6G+, clone: RB6-8C5, 1:100), F4/80 (1:80), Tim-4 (clone: F31-1224 1225 5G3, 1:100), CCR2 (clone: SA203G11, 1:100). Gating for FACS: Myeloid cells: DAPI-CD45+CD11b+; neutrophils: DAPI-CD45+CD11b+Ly6g+ cells, further parsed by LY6C; T-1226 regulatory cells: DAPI-CD45+CD11b-TCRb+CD4+, further parsed by FOXP3; resident 1227 macrophages: DAPI-CD45+CD11b+F4/80+ GR1- (Ly6c+,Ly6G+), further parsed by 1228 TIMD4+CCR2-. 1229

Conditioned media. P3 primary cultures were seeded on 96-well plates (Nuncio, 167008) at a 1230 density of 50,000-60,000 cells/well. We used the pre-plating technique to exclude CMs⁶⁵, by 1231 washing the cultures 3 h after isolation and growing only the adherent cells, which were mainly 1232 1233 CFs, myofibroblasts and ECs. Two days afterwards, the cells were incubated with either mannitol or 30 µg/ml GA for 10 h, after which they were washed twice with PBS to discard all residual GA 1234 1235 and incubated in fresh medium. The medium was collected after 12 h, passed through a 0.22-µm 1236 cell strainer (Durapore Membran, SLGV033R, Merck Millipore, Cork, IRL) and kept at -20°C until use for ROS assay. 1237

1238


1239

1241 Supplementary Figures




1243 Figure S1: Cluster annotations and flow cytometry gating. A, Distinct cell populations are

- 1244 visualized in UMAP dimensionality reduction plots. Cluster annotation was performed using
- 1245 canonical markers for each cell type. **B**, Myocardial neutrophil infiltration was analyzed using
- 1246 FACS. Gating data are provided. C, number of myocardial Timd4+ resident macrophages was
- 1247 analyzed using FACS. Gating data are provided.




1250	Figure S2: GA promotes a protective and proangiogenic effect on endothelial cells at 1 dpi.
1251	A, A targeted UMAP performed on the subset of endothelial cells. B, IPA performed on DEG
1252	comparing GA and Control on the cluster of ECs from the general UMAP (adjusted <i>p</i> -value <0.05).
1253	C, Capillary-3 and monocytic clusters accumulate on 4 dpi. D, A frequency plot, showing the
1254	relative abundance of endothelial capillaries 1 and 2 at 1 dpi. Capillary-2 was more abundant in
1255	the GA-group, while Capillary-1 was more abundant in the control group. E, An unbiased heatmap
1256	of the cluster markers of Capillary-1 and Capillary-2 (adjusted p-value <0.05). G, Pathway
1257	analysis using the DAVID tool of the cluster markers for Capillary-1 and Capillary-2.



1259 Figure S3: GA promotes a biphasic fibroblast response following acute MI in mice.

1260 A, A targeted UMAP of fibroblast subset from the general UMAP showing a distinct cluster separation of fibroblasts, double-marker monocytes positive also for fibroblast genes, probably 1261 reflecting fibroblast phagocytosis, pericytes and glial cells. B, Myofibroblasts as well as the 1262 double-markers monocytes are absent at 1 dpi, and they strongly appear at 4 dpi. C, cluster markers 1263 used for annotations. **D**, IPA performed at Days 1 and 4 post injury on the DE genes between GA 1264 and Control of the quiescent fibroblast cluster (adjusted P-value <0.05). While at 1 dpi there is a 1265 strong fibroblast activation, an important contributor for wound healing, at 4 dpi there is a marked 1266 fibroblast silencing, that might reflect a decreased tendency for a fibrotic scar formation. 1267



13.1	19 1977 - 1977	A.
	n le m	Aug.
N.		*
	(0)	A
·		
	Re	A sea
		We the state
te		

Stats: Merged Data	
Mean:	128.3 nm
Mode:	79.2 nm
SD:	69.0 nm
D10:	73.4 nm
D50:	106.0 nm
D90:	212.4 nm
Stats: Mean +/- Star	ndard Error
Mean:	133.4 +/- 9.3 nm
Mode:	86.9 +/- 6.5 nm
SD:	69.1 +/- 5.9 nm
D10:	78.4 +/- 5.4 nm
D50:	109.5 +/- 7.3 nm
D90:	224.5 +/- 18.7 nm
Concentration:	1.08e+09 +/- 1.52e+08 particles/ml
	58.8 +/- 8.3 particles/frame
	72.0 +/- 7.2 centres/frame

D

0

0

200

300 400 500 600 700 800 900 1000

			Number	%
Protein Full Name	Protein_Key	Gene	of	Sequence
			Peptides	Coverage
Glyceraldehyde-3-	P16858	Gapdh	48	92.192
phosphate				
dehydrogenase				
Heat shock cognate	P63017	Hspa8	66	86.533
71 kDa protein				
Caveolin	D3Z0J2	Cav1	5	70.213
Tubulin beta-3 chain	Q9ERD7	Tubb3	22	56.889
Programmed cell	Q9WU78	Pdcd6ip	41	48.677
death 6-interacting				
protein (ALIX)				
Heat shock 70	P17879	Hspa1b	28	46.262
Caveolae-associated	Q63918	Cavin2	15	41.866
protein 2	000010	Cavinz	15	41.000
Tumor susceptibility	Q61187	Tsg101	16	41.176
gene 101 protein		-		
CD81 antigen	P35762	Cd81	2	17.797
Syntenin-1	O08992	Sdcbp	5	16.388
Exosome complex	Q8BTW3	Exosc6	2	14.652
component MTR3				
Integrin beta-1	P09055	ltgb1	8	12.281
Flotillin	G3UYU4	Flot1	3	11.579
CD63 antigen	A0A1W2P8C6	Cd63	2	10.976
Platelet endothelial	B1ARB3	Pecam1	3	5.738
cell adhesion			_	
molecule				
Integrin alpha-7	G3X9Q1	ltga7	3	5.458

1270 Figure S4: Validations for EV isolation

- 1271 A, Schematic illustration for EV isolation protocol from mouse LV tissue. EVs were purified by
- sequential centrifugations at increasing speed up to 100,000 g. Subsequently, EVs were analyzed
- 1273 to confirm high-purity isolation. **B**, Transmission electron microscopy. Samples were stained with
- 1274 2% uranyl acetate, revealing membrane-enclosed particles of the anticipated diameter. Scale: 100
- 1275 nm. C, Nanoparticle tracking analysis (NTA) demonstrates a unimodal pick below 200 nm,
- 1276 consistent with EVs diameter. **D**, Data from proteomic analysis. Common EV-specific protein
- 1277 markers were detected using mass-spectrometry.

1278






Figure S5: CD31+SMA+ colocalize in the walls of blood vessels. A, Representative images of cardiac sections, at 4 dpi of control (upper row) or GA (lower row). SMA+ areas (*left*) representing activated fibroblasts, adjacent to arterial blood vessels (circular structures), which are stained positive also for CD31+ (*right*). Webb-like structures staining solely for CD31+ (*middle*) represent


1285 capillaries. Scale bars: 400µm. **B**, A higher magnification of a SMA+CD31+ blood vessel,



1286 representing an artery. Scale bars: 200µm.




1293	EVOC that were exposed to H_2O_2 . Scale bars: 500 μ m. E, Higher magnifications of D, showing
1294	CMs positive for TUNEL. Scale bars: 20µm. F, Representative images of control and GA treated
1295	EVOC that were exposed to H_2O_2 and stained for the DNA double-strand breaks marker γ H2AX.
1296	Scale bars: 500 μ m. G , Higher magnifications of F, showing CMs positive for γ H2AX. Scale bars:
1297	20 μ m. H, Quantification of % γ H2AX positive cells (n=3 for each group, an average of 550 cells
1298	were counted for each group).
1299	
1300	
1301	
1302	
1303	
1304	
1305	
1306	
1307	
1308	
1309	
1310	
1311	




1326

1327 Fig S7: Models summarizing the pleiotropic beneficial effect of GA on the injured heart.

Illustrations summarizing the effect of GA on multiple cardiac cell types and the crosstalk between
them (upper). Black and grey arrows represent direct and indirect effects, respectively. The effect
of GA on distinct cell populations is demonstrated by the time course of the cells' participation in
the repair process (lower).





A, FACS analysis of P3 cultures used for the *in vitro* experiments reveals negligible amounts of immune cells in the cultures. **B**, P3 cultures were treated either with STS alone or with STS + GA. Apoptotic CM death was measured by DAPI exclusion assay 18h after the addition of STS. Arrows point to dying cells ($n_{PBS} = 4$, 700 cells; $n_{GA} = 5$, 1321 cells). Scale bars: 300 µm. **C**, P3 cultures


were treated with FITC-GA for 48h, followed by treatment with 1 µM H₂O₂ for 2h, DAPI 1339 exclusion assay was performed to determine the levels of cell death, followed by staining with 1340 anti-cTnT (red). Arrowheads point at cTnT+DAPI- cells, representing live CMs in GA-treated 1341 (top) and control cultures (bottom left). Bottom right panel shows the quantification of the fold 1342 change in cTnT+DAPI+ dead CMs between the two groups (n=3 for each group). In total, 1248 1343 cells were counted. Scale bars: 200 µm. D, Representative images of adherent cells at 3h cultures, 1344 1345 showing that most of the cultures contain CFs (vimentin) and ECs (CD31), whereas CMs (cTnT) are mainly non-adherent at this time point. Scale bars: 750 µm. E, A scheme showing the 1346 experimental design of the conditioned media assay. F. DAPI exclusion assay following challenge 1347 with H₂O₂ and treatment with conditioned medium. Quantification of the fold-change in 1348 cTnI+DAPI+ (right) (n=3, 1487 cells). Scale bars: 300 µm. G,H, P3 cultures were treated with 1349 either GA or control for 48h and co-stained with anti-vimentin and anti-pH3 (G) or anti-vimentin 1350 and Ki67 (H). Quantifications show less proliferation of CFs compared to control (n=3 for each 1351 group). In total, 2482 and 3616 cells were counted for GA and PBS, respectively. Scale bars: 200 1352 1353 μm. I, Representative fields (left) and quantification (right) show less proliferation of CFs in GAtreated cultures derived from human biopsies. Scale bars: 150 μ m. (n = 3, more than >3000 cells 1354 for each group). 1355

	Total	GA	Standard care	Pvalue	
	(N=12)	(N=7)	(N=5)	Fvalue	Serum NT-proBNP - mean ± SD (pg/mL)
Age, median (IQR) -yr	72	73 (64-75)	71 (71-77)	0.4	Baseline Day 2 Day 14
Male sex -no. (%)	10 (83.3)	E (74.4)	5 (100)	0.47	All patients (n=12) 4126±1046 3211±1224 2894±1256
Male Sex -110. (%)	10 (83.3)	5 (71.4)	5 (100)	0.47	GA group (n=7) 4866±4795 2345±2169 2006±1963
Body-mass index, median (IQR) –m/kg2	31.1	29.5 (25.8-40.3)	34.7 (28.5-40.3)	0.75	Standard care group (n=5) 3387±2026 4077±2961 3783±2268
Coexisting conditions -no. (%)					C Rehospitalizations for Heart Failure
Diabetes	10 (83.3)	5 (71.4)	5 (100)	0.47	
Dyslipidemia	10 (83.3)	5 (71.4)	5 (100)	0.47	
Chronic renal failure	6 (50)	3 (42.8)	3 (60)	0.99	
Hypertension	11 (91.6)	6 (85.7)	5 (100)	0.99	
Tobacco use	11 (91.6)	6 (85.7)	5 (100)	0.99	
Prior cardiac Intervention –no. (%)	10 (83.3)	5 (71.4)	5 (100)	0.47	% HF hospitalizatio-free survival
CABG	4 (33.3)	1 (14.3)	3 (60)	0.22	
PCI	9 (75)	4 (57.1)	5 (100)	0.20	
Prior MI	8 (66.7)	4 (57.1)	4 (80)	0.58	
Arrhythmias	7 (58.3)	3 (42.8)	4 (80)	0.29	
Medical therapy –no. (%)					0 10 20 30
Aspirin	9 (0.75)	4 (57.1)	5 (100)	0.20	7
Beta blockers	10 (83.3)	5 (71.4)	5 (100)	0.47	# Patients at risk
Statins	10 (83.3)	5 (71.4)	5 (100)	0.47	7 6
Diuretics	11 (91.6)	7 (100)	4 (80)	0.42	5 4 3
ACEi/ARB	8 (83.3)	5 (71.4)	3 (60)	0.99	
Aldactone	7 (58.3)	4 (57.1)	3 (60)	0.99	0 4 9 13
SGLT2 inhibitors	5 (41.6)	3 (42.8)	2 (40)	0.99	Time in days
Sacubitril/Valsartan	3 (25)	2 (28.6)	1 (20)	0.99	1

1356


1357 Figure S9: Additional data of the patients that participated in the clinical trial.

A, An extended list of baseline patient characteristics, including demographics, cardiovascular co-1358 morbidities and medical therapy. Continuous variables are presented as median and interguartile 1359 1360 range (IQR), discrete variables as proportions. **B**, Raw values of serum NT-proBNP in the entire cohort according to treatment group. NT-proBNP were markedly decreased already at 2 days after 1361 initiation of GA therapy, while the opposite trend was observed in the control group. 14 days after 1362 1363 hospitalization, NT-proBNP levels were close to baseline levels in the control group, but still markedly lower in the GA-treated group. C, Kaplan-Meier curve showing HF hospitalization-free 1364 in the 3 months following enrollment. Although the number of re-hospitalizations was small (n=3), 1365 1366 the relative reduction in risk of rehospitalization in the GA-treated group is 64%.



Human EVs: Common EV-specific markers found in proteomic analysis

Protein Full Name	Protein_Key	Gene	Number of Peptides	% Sequence Coverage
CD5 antigen-like	O43866	CD5L	43	86.167
Fibronectin	P02751	FN1	185	73.96
Actin, cytoplasmic 1	P60709	ACTB	19	58.133
Fibulin-1	P23142	FBLN1	36	56.899
Galectin-3-binding protein	Q08380	LGALS3BP	31	50.598
Monocyte differentiation antigen CD14	P08571	CD14	10	36.533
Lactotransferrin	P02788	LTF	18	34.93
Glyceraldehyde-3-phosphate dehydrogenase	P04406	GAPDH	8	32.239
Scavenger receptor cysteine- rich type 1 protein M130	Q86VB7	CD163	13	14.879



1385 Figure S10: Proteomic analysis of EV-enriched serum from patients with ADHF

Proteomic analysis was performed using mass spectrometry on sera from patients that participated 1386 in the clinical trial. The sera were enriched for EVs using ultracentrifugation. A, Nanoparticle 1387 tracking analysis, demonstrating that the majority of particles detected are below 200 nm, 1388 averaging 106 nm, characteristic of EVs. B, Transmission electron microscopy. Samples were 1389 1390 stained with 2% uranyl acetate, revealing multiple vesicles. Scale: 100 nm. C, Proteomic analysis 1391 showing characteristic protein markers for EVs, suggestive of an EV-enriched serum. **D**, Principal component analysis at three timepoints: baseline, day 2 and 14. At baseline all samples are 1392 scattered randomly. Starting at day 2, a separate cluster of GA-treated patients is apparent, 1393 1394 suggesting a common set of enriched proteins. E, A heat map of day 2, generated from DE proteins in ANOVA, using mean intensities transformed on log2. Dendrogram showing clustering 1395 1396 according to treatment, and a distinct pattern of proteome expression is evident. F, Individual 1397 proteins that were found to be differentially expressed at day 2, shown as fold-change from baseline levels. 1398

1399

1400

1401

1402